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“A COMPARATIVE AND CORRELATIVE STUDY OF SERUM HOMOCYSTEINE 
LEVEL IN GESTATIONAL DIABETES MELLITUS AND NORMAL PREGNANCY’’ 
                                                                                ABSTRACT  
Background : 
 Gestational diabetes (GDM) is defined as carbohydrate intolerance that begins or is first 
recognized during pregnancy. Homocysteine is naturally obtained by diet containing  
methionine  which is one of the essential amino acids. The role of homocysteine is an 
independent risk factor of gestational diabetes mellitus has not been extensively studied in 
India. Due to multiple factors like dietary, life style, socio economic status and other ethnic 
differences, the results found in the western studies cannot be applicable to our population. 
Aims and Objectives:  
The aim of this study is to study the association of serum homocysteine levels in gestational 
diabetes mellitus and to compare the serum homocysteine levels in gestational diabetes mellitus 
and in normal pregnancy.  
Methods:  
This case control study comprised 30 patients with gestational diabetes mellitus and 20 patients 
of normal pregnancy in the age group of 18 to 35 years attending Obstetrics and Gynaecology 
department OPD or admitted to Rajamerasutar Hospital, Thanjavur Medical College, 
Thanjavur,  
 
 
 
  
 
 Serum Homocysteine, Glucose, Urea, Creatinine, Total Cholesterol, Triglycerides, were 
determined. Data were analyzed with appropriate statistical analyzer.Serum homocysteine 
levels were estimated in all of them and its correlation to gestational diabetes mellitus and in 
normal pregnancy was studied.  
Results:  
The serum homocysteine levels were statistically higher among the cases as compared to the 
controls. The mean value of serum homocysteine in control group is 3.8 ± 0.95 and in  
gestational diabetes patients is 16.30 ± 6.09. Its ‘p’ value is significant ( p .000 < 0.05) . Total 
cholesterol level is significantly elevated in gestational diabetes patients. The mean value of 
Total cholesterol in control group is 187.70±18.2 and in gestational diabetes patients is 211.50 ± 
28.799. Its ‘p’ value is significant   ( p=0.002). In our study, 12 patients of gestational diabetes 
patients had elevated serum Triglyceride level. In control group, all had the normal triglyceride 
level. The mean value of serum triglyceride level is 113.30 ± 16.10 in control group. In study 
group (gestational diabetes patients) , the mean value is 140.20 ± 22.15.  
Conclusion: 
There is significant association between homocysteine with gestational diabetes mellitus. 
Higher homocysteine levels were observed with gestational diabetes mellitus. 
Hyperhomocysteinemia is found in 56.66% of patients with gestational diabetes mellitus.  
 
 
 
  
Hyperhomocysteinemia is found to be an independent risk factor for gestational diabetes 
mellitus patients. The average levels of Total cholesterol, were significantly found to be higher 
in GDM cases compared to controls. 
 
Keywords Homocysteine; Hyperhomocysteinemia; Gestational diabetes mellitus. 
 
 
 
 
                       
                
               
                  
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
                                                    INTRODUCTION 
 
                           Diabetes Mellitus is a common disease with many complications.  
It occur due to combination of multiple factor such as hereditary and 
environmental factors resulting in hyperglycemia and their complications. One of 
the independent risk factor is increased serum Homocysteine.                         
                          Diabetes during pregnancy can be the cause of poor outcome not 
only for mother during pregnancy but also for the child. Children born to GDM 
mothers have an increased risk of developing obesity and type 2 DM in the future. 
These mother also have a higher risk of developing type 2 DM in the future. 
                        The prevalence of GDM in india may range from 3.8 to 21 % of all 
pregnancies. GDM has been more prevalent in urban areas than in rural areas. 
                         Appropriate management of diabetes in pregnancy is essential as it 
is related with complications like cesarean section in women, macrosomia 
hypoglycemia , hypocalcemia and hyperbillirubinemia in new borns. 
                        During the past 2 decades, hyperhomocysteinemia has emerged as a 
risk factor for cardiovascular disease. Deleterious effects of homocysteine on 
endothelial function are explained in various studies. However, its relationships to 
and role in the onsets of DM are unclear. 
  
                       Meigs et al(1) reported that increased serum Homocysteine is 
associated with increased insulin level in blood and suggested that it may cause 
cardiovascular disease risk when it is  associated with insulin resistance. 
                                  
                        
  
  
 
OBJECTIVES 
 
1. To study the association of serum homocysteine levels in gestational diabetes 
mellitus.  
 
2. To compare the serum homocysteine levels in gestational diabetes mellitus and 
in normal pregnancy. 
 
 
 
 
 
 
 
 
 
  
  
 
REVIEW OF LITERATURE 
 
                            The earliest description of diabetes was given by the Ancient 
Greek physician Aretaeus of Cappadocia(2)  (2nd century AD). An ancient Egyptian 
papyrus, explain the diabetes as a disease that caused a person to melt in the loins 
and the resultant urine to attract ants (due to the high sugar values).  
                         The name itself explains valuable body fluid loss. Diabetes was 
probably coined by Apollonius of Memphis(2)  around 250 BC. Diabetes   meaning 
“to siphon” is from a Greek word, Mellitus, a Latin word, meaning is “sweet 
taste”.  Madhumeha   was  identified  by the great Indian physician  Sushruta(2) and 
he further identified the risk factor such as  obesity and sedentary lifestyle,  and he 
advised exercises to help in curing. 
                              Early diabetes research linked to glycogen metabolism and in 1869, 
Paul langerhans, a medical student discovered the pancreatic islet cells. In 1916, 
sharpey–schafer suggested that a single chemical was missing in pancreas and that 
was insulin. EL scott and Nikolae Paulescu, from the pancreas of experimental 
dogs, they were extracting insulin successfully. 
 
 
  
                        In 1921, FG Banting discovered the insulin, the extract name is 
“isletin” and he received nobel prize in 1923. A 14 years boy, leonard was the first 
patient who received the banting -extract insulin. In 1936 sir Harold Himsworth 
found that diabetes falls on 2 types based on “insulin insensitivity”. 
                      First description of GDM, by the patient fredecia who was admitted 
in berlin infirmary in 1823 during her 7thmonth of 5th pregnancy(3).The paper titled 
”ON PUERPERAL SEPSIS”  was presented by Mathews Duncan in 1882 . 
                     The real diabetic knowledge came in 1922 with invention of insulin 
by Best and Banding. He gave the total change in morbidity and mortality 
associated with GDM. 
                   The management of GDM was an art and science developed by Dr. 
Elliot proctor Joslin of Boston. Later it was continued by Dr. pricilla white. After 
that the knowledge about diabetes mellitus is growing dramatically. 
                  “PREDICAMENT” term used by Gilbert and Dunlop(4).It denotes the 
time interval before the disease diagnosis and they retrospectively  analyzed in 
overt diabetic following  obstetric  history, they found that 50% fetal loss occurs 2 
years preceding the diagnosis. 
 
                    In 1952, jackson was stated that the predicament is clinical diagnosis 
made by previous obstetrical history. In 1956, Lewis extended this definition based 
  
upon the over weight babies and fetal loss before the diagnosis of increased 
glucose level and abnormal blood test reports was made. 
                       Miller et al(5) in 1944 and Mengert and Laughlin (6) reported the fetal 
loss during the pre-diabetic state.  Pedowitz and shleva in 1957 and Hagbard in 
1958 found that the risk of prenatal death shortly before the diagnosis of diabetes. 
                      In 1967 in Copenhagen, Jorgen Pederson was used first the term 
gestational diabetes. 
 
 DEFINITION: 
                    Gestational diabetes mellitus(7), is defined as any degree of glucose 
intolerance with onset or first recognition during pregnancy. This definition 
includes women whose glucose tolerance will return to normal after pregnancy and 
those who will persist with glucose tolerance and type 2 DM. 
 
INCIDENCE AND PREVALENCE: 
                    In 2012,  371  million people had diabetes, the number may increase to 
552  million by 2030(8). Globally the incidence of type 2 DM is rising. In that 
eighty percentage of the diabetes population live in, developing countries and 
common age distribution between 40- 50 years of age. 78,000 children develop 
type 1 diabetes in each year. 
  
                  
                      Asian Indians have a higher genetic predisposition for developing 
DM of type 2 and its complications. A unique combination of clinical and 
biochemical parameters have identified and labeled as “Asian Indian phenotype”(9). 
Because the Asian Indians have a higher degree of central obesity and other risk 
factors. 
                   The incidence of GDM, depending upon the population studied, may 
range from o.5 to 12.5 % of all pregnant women(10, 11).  Prevalence is more in 
African, Hispanic, Native american than white women. The incidence of GDM 
higher in population with higher type 2 DM prevalence. When compared the 
Caucasian women and Indian women, Indian women have 11 fold increased 
glucose tolerance during pregnancy. 
 
Table-1:PREVAIENCE OF GESTATIONAL DIABETES AROUND THE 
WORLD: 
COUNTRY PREVALENCE % AUTHOR 
 England 0.15 Lind  
Ireland 0.2 – 3.5 Hadden  
Australia 0.7 Abell, besicher 
Sweden 1.3 Stangenberg  
Denmark 1.7 Guttorm  
Kenya  1.8 Fraser  
Scotland  4.0 sutherland 
USA 2.7 – 7.5 in Boston and 
12.3 in Los Angeles 
O’sullivan 
Mestman  
  
 
                               The increasing prevalence in developing countries is related to 
increasing urbanization, decreasing physical activity, changes in dietary patterns 
and increasing prevalence of obesity. Women with GDM and their children are at 
risk of developing DM in future, so special attention should be paid to these 
patients in developing countries. 
 
Table-2: Asian prevalence of Diabetes mellitus (urban) 
 SRI LANKA INDIA PAKISTAN 
Diabetes mellitus 12.7% 12.1% 12.0% 
IGT 14.4% 14.0% 10.0% 
 
                  Gomez et al (12) and Das et al (13) found that 25 % and 50% 0f women 
with GDM had obesity and Family history of diabetic was present in both studies 
with 77.3% in Gomez and 14.3 % in das studies. 
 The classification adapted by World health organization (14) is : 
                                   1. Diabetes mellitus. 
                                   2. Impaired glucose tolerance 
                                        3. Gestational diabetes mellitus. 
 
  
                        A Small proportion of type 1 diabetics are difficult to control and 
are called“ Brittle diabetics or Labile diabetics”(15). It defined as patients whose life 
is constantly, disrupted by alternative episodes of decreased or increased glucose 
level whatever be the cause. 
 
 
TYPE 2 DIABETES MELLITUS:   
                            Impaired beta cells function, so relative insulin deficiency and 
insulin resistant. Some of the gene have  the positive co-relation with type 2 DM 
such as Insulin gene hvr, apolipoprotein D, glucocorticoid, glucokinase and 
complement C4B2. 
 
THEORY OF GLUCOSE TOXICITY: 
                   In Type 2 diabetes mellitus, earliest feature is loss of normal pulsatile 
pattern of insulin secretion in the basal fasting state, then decrease in the amplitude 
of insulin secretory pulses in the postprandial phase. Later first phase of insulin 
release is reduced due to selective glucose unresponsiveness of the beta cell. This 
is due to direct glucose toxicity of the beta cell. The initial Pancreatic damage, 
characterized by defective insulin gene expression (16). . 
 
 
  
ROLE OF GELANIN:  
                     It is a hormone which has inhibitory effects on insulin. This is 
implicated in etiopathogenesis of type 2 DM and malnutrition related diabetes 
mellitus.            
                     Nutrition deficiency (zinc and selenium deficiency) 
                                                           
                                      Excess of free radical stress 
 
                                        Lipid peroxidase 
 
                                       Beta cell damage protein calorie deficit leads to 
glucose intolerance and diminished insulin response. 
 
PANCREATIC AMYLOID-AMYLIN IN TYPE 2 DM: 
                     Opie was first to describe pancreatic amylin in 1901. Amylin is 
produced by beta-cell and is localized with insulin in the secretory granules and is 
secreted along with insulin and pro-insulin. Amyloid deposits are seen in type 2 
DM.  Amylin antagonizes insulin action. It inhibits pancreatic insulin secretion, in 
muscle inhibits glycogen synthesis and causes peripheral insulin resistance (17). 
 
  
 GESTATIONAL DIABETES MELLITUS:  There are two classification 
method for gestational diabetes mellitus.  
 A. white classification and  
 B. ADA classification. 
A. WHITE CLASSIFICATION: Named after Priscilla White(18) . This is widely 
used to assess maternal and fetal risk. It help to distinguish between 
gestational diabetes (type A) and pre-gestational diabetes. It is further 
subdivided in to  
 Type A1: Abnormal oral glucose tolerance test (OGTT), but normal blood 
glucose levels during fasting and two hours after meals; Diet modification is 
sufficient to control glucose levels. 
 Type A2: Abnormal OGTT compounded by abnormal glucose levels during 
fasting and/or after meals; Additional therapy with insulin or other medications 
is required. 
 
Pregnant women with pre-existing diabetes is split up into  
o Type B: Onset at age twenty or older and duration of less than ten years. 
o Type C: Onset at age ten to nineteen or duration of ten to nineteen years. 
 
 
  
o Type D: Onset before age ten or duration greater than twenty years.  
 D1- Onset before the age of 10         
 D2- Duration over 20 years 
 D3-Macrovascular disease 
 D4-Microvascular disease/hypertension but not preeclampsia. 
 
o Type E: Overt diabetes mellitus with calcified pelvic vessels. 
o Type F: Diabetes nephropathy over 500mg/day proteinuria, 
o Type R: Proliferative retinopathy and vitreous haemarrhage, 
o Type RF: Both retinopathy and nephropathy. 
o Type H: Ischemic cardiac disease, 
o Type T: Prior kidney transplant. 
 
B. ADA classification. 
• Type 1 DM before pregnancy, 
• Type 2 DM before pregnancy OR  
• First time becoming diabetic during pregnancy-gestational diabetes 
mellitus. 
 
 
  
 
                  However the end results is hyperglycemia, which is responsible for 
the symptoms such as polyuria, polydipsia, polyphagia, blurred vision, 
unexplained weight loss, lethargy and inefficient energy metabolism. Insulin 
resistant is the main cause. 
 
WHAT IS INSULIN SENSITIVITY? 
                  It is a state where a small amount of insulin able to produce severe 
hypoglycemic effect, in a diabetic patient who has been controlled with OHA or 
insulin(19)..  
Mechanism: 
         1. Decrease in the rate of insulin metabolism and exertion. 
         2. Decrease secretion of counter regulatory hormone, 
         3. Increased secretion of insulin or insulin like hormones. 
                         
                     In pregnancy, diabetics on insulin can develop frequent attacks of 
hypoglycemia in 1st trimester due to poor diet and pregnancy induced vomiting. 
And also in the first 24- 28 hrs of delivery, insulin requirement suddenly reduces 
because of the fall in levels of estrogen, progesterone and HPL which have anti- 
insulin effect. 
  
 
 
INSULIN RESISTANCE:  
                    It is a state in which a normal amount of insulin produces a sub normal 
amount of insulin response(20).. Its fall in to 2 categories: 
 
1. DECREASED SENSITIVITY:  
            Where normal response can be obtained with maximum insulin level. 
2. DECREASED RESPONSIVENESS:  
           Even large amount of insulin cannot bring the normal response. 
 
                Depending on the molecular mechanisms involved insulin resistance 
may be at pre-receptor, receptor, and post-receptor. Most common is post-receptor 
level. 
 
PATHOPHYSIOLOGY OF INSULIN RESISTANCE: 
1. Abnormal insulin secretion 
2. Resistance to insulin action in target tissues. 
 
 
  
Insulin resistance causes and associated conditions: 
Genetics              Obesity and Inactivity             Aging              Medication     
 
                         
                                  INSULIN    RESISTANCE 
 
 
Type 2 DM         Hypertension             Dyslipidemia              Atherosclerosis 
There are three phase of development of type-2 DM, 
 Phase 1- Euglycemia with increased insulin levels, 
 Phase 11- Postprandial hyperglycemia with increased insulin levels, 
 Phase 111 – Overt diabetes with declining insulin levels. 
Insulin resistance in Type 2 DM  is  at  post-receptor level. The substance 
responsible for this is amylin. 
Insulin resistance, hyperinsulinemia and hyperlipidemia often co-exist.  
The typical pattern of a lipid profile in Insulin resistance is; 
 Decreased serum HDL – cholesterol 
 Increased serum very low density lipoprotein( VLDL) 
 Less common elevation of LDL , 
 Increase in triglyceride. 
  
 
 The American diabetes association (ADA) in its newer classification retained 
the state of impaired  glucose  tolerance and introduce another term impaired  
fasting  glucose (21).. 
          Table-3: 
TIME IMPAIRED GLUCOSE TOLERANCE 
Fasting < 126 mg/dl 
Two hour ≥ 140 mg/dl -199 mg/dl 
 
 IMPAIRED  GLUCOSE  TOLERANCE (IGT): 
 Two hours glucose levels of 140- 199mg/dl after 75 gm of oral glucose is 
called as IGT. 
 IMPAIRED  FASTING  GLUCOSE (IFG):  
Glucose level of 100 –125 mg/dl in fasting patients is called as IFG. 
The following  risk associated with Impaired glucose  tolerance ,  
 Coronary artery disease. 
 Progression to type 2 DM, 
 Cognitive impairment in elderly people 
 GDM induces embryopathy as well as increase fetal morbidity and 
mortality. 
  
 
PATHOPHYSIOLOGY  OF  IGT:  
                 Abnormality may be intracellular  glucose metabolism namely defective 
non-oxidative glucose storage. The loss of first phase of insulin secretion is a well 
known early changes in IGT. But in second phase of insulin secretion remained 
normal. So person with IGT have higher than normal insulin level but insignificant 
to overcome the resistance. IGT is characterized by hyperglycemia with 
hyperinsulinemia. 
                    Elevated level of fasting insulin level associated with impaired 
fibrionlysis and hypercoagulopathy. Hyperglycemia dependent oxidative stress 
leads to endothelial dysfunctions. Increased triglyceride level could cause 
decreased insulin sensitivity via raised nonesterified free fatty acids. 
    
 RISK FACTOR ASSOCIATED WITH GDM: 
 Maternal factors such as : 
- Maternal age 
- Higher parity 
- Pre-pregnancy weight 
- Pregnancy weight gain 
- BMI > 27 
  
- Short stature 
- Smoking 
- Non white ethnic origin 
- α-Thalassaemia trait 
- Polycystic ovary syndrome 
- High intake of saturated fat 
 Family history: 
- Family history of type 2 diabetes 
- GDM in woman 
 Previous obstetric outcome: 
- Congenital malformation 
- Stillbirth 
- Macrosomia 
- Caesarean section 
- Previous GDM 
- Previous Low birth weight baby 
 Pregnancy factors: 
- High blood pressure in pregnancy 
- Multiple pregnancy 
- Polyhydraminosis 
  
 
 Protective factors: 
- Young age 
- Alcohol use 
CARBOHYDRATE METABOLISM IN NON PREGNANT STATE: 
 
ACTION OF INSULIN: 
1. It promotes glucose uptake by skeletal muscle 
2. Glycogen synthesis 
3. Suppression of gluconeogenesis 
4. Lipolysis by liver. 
                The body tissue obtained the energy from glucose in the systemic 
circulation.  Carbohydrate are the most important source. Brain cells derive energy 
from glucose.  
Glucose after entering the cells has 2 metabolic pathway. 
1. Oxidative metabolism  = glucose                         glucose -6 -  phosphate            
glycolysis                        ATP production                                 
2. Non oxidative metabolism:  glycogen formation. 
     Prime regulator is insulin. 
 
 
  
      
                              
                                      
                                                 
 
 
                                        
 
                                                     
 
 
                                              
 
 
 
 
POST PRANDIAL PHASE: 
                           Insulin production decreased after 2 to 3 hours of meal, and also 
after prolonged fasting. Gluconeogenesis pathway activated during fasting to 
produce glucose by using protein and fat breakdown. This  endogeneous  glucose 
production maintains the energy. 
   Carbohydrate diet 
Plasma glucose raised 
Changes detected by 
pancreatic beta cells 
Insulin secretion 
Muscle and adipocyte 
glucose uptake
Aminoacid  uptake by 
muscles 
Decreased lipolysis in 
adipocytes and FFA level 
Increased glycogenesis 
Decreased gluconeogenesis 
Decreased glycogenolysis 
  
FASTING PHASE: 
• After 12 hour of diet, Gluconeogenesis is the source of energy. it needs 
aminoacid so protein catabolism will occur. 
• And also fat breakdown leads to production of glycerol and fatty acids 
resulting in glucose and ketone body formation 
• But ketone bodies rapidly cleared from circulation. 
• Insulin acts as both anabolic and catabolic in well fed state. 
• FFAs important for maintaining insulin secretion during prolonged fast. 
In 1950, Burt, Frenkel and Goodner found that pregnancy was associated with 
certain physiological changes in carbohydrate metabolism. Continuous  supply of 
glucose and other nutrients to fetus through placenta. 
 
CARBOHYDRATE METABOLISM IN GDM AND IN PREGNANCY: 
                     Pregnancy characterized by gradual increasing insulin resistance that 
starts near mid pregnancy and progresses through the third trimester. It is important 
to note that insulin resistance return to near normal in post delivery, suggesting  the 
placental hormones plays important role in the pathogenesis. 
                 The cumulative effects of maternal adiposity and placental influences 
results in insulin signaling pathway dysfunction, which lead to decreased glucose 
uptake and an increase in insulin resistance. The placenta produces human 
  
chorionic somatomammotropin or the human placental lactogen which stimulates 
pancreatic secretion of insulin in the fetus and inhibits peripheral uptake of glucose 
in the mother. 
                    All pregnant women become insulin resistance out of that only 10% 
will have GDM. Buckman and co workers found that in pregnant women first 
phase of intravenous glucose response significantly reduced compare to normal 
pregnancy. Catalano and coworker(22,23) found the hepatic insulin resistance in 
GDM. 
 Effect of pregnancy on DM on various stages: 
Table-4: 
   
First 
trimester 
Improve-carbohydrate 
metabolism,Hypoglycemic 
reaction, increased sensitivity to 
insulin. 
Poor intake due to 
hyperemesis gravidorum, 
maternal glucose enter 
into foetus 
Second 
trimester 
Insulin need increases, ketosis 
prone 
Anti-insulin hormone are 
acting and degenerarion 
of insulin by placenta 
Third 
trimester 
Greater intensification of diabetic 
status 
Anti-insulin hormone are 
acting. 
Labour  Hypoglycemia,Increased 
sensitivity to insulin 
Due to increased physical 
activity,Insulin sensitivity 
increases 
postpartum Remission in DM , insulin need 
falls 
Once the placenta is out 
anti-insulin effect has 
gone. 
 
Changes noted       Possible causes 
  
 HORMONAL RESPONSES TO GDM: 
 ESTROGEN: Increasing the insulin level and also its binding capacity(24). 
 PROGESTRONE: 
1. Insulin response to glucose is increased. 
2. Glucose transport decreased(24). 
3. Insulin receptor number decreased 
4. Insulin response is decreased to suppress the endogenous production of 
glucose. 
 CORTISOL: 
1. Insulin resistance by post receptor mechanism(25)  is due to increased 
Maternal cortisol level in last trimester.  
2. Hepatic glucose production is increased. 
3. Promotes  lipolysis                increase FFA 
4. Protein breakdown               increase aminoacids. 
 HUMAN PLACENTAL LACTOGEN: 
1. Its level increases as pregnancy advances 
2. Maximum role for insulin resistance. 
3. It directly acts on pancreatic beta cell to stimulate insulin secretion. 
 
 
  
4. Glucose transports are decreased. 
5. It stimulates IGF-1production through cell surface receptor. 
 
 PLACENTAL GROWTH FACTOR: 
                       Secreted  by placenta. It has anti insulin action. 
 PROLACTIN:  
                  It increases 10 fold of normal level. In women with 
hyperprolactinemia have increase basal insulin and decreased glucose transport.   
                      After the mid trimester, the placental size increases with increasing 
the above hormones, which results in a more insulin resistant state. Insulin 
sensitivity also affected by elevated level of estrogen, progesterone and prolactin. 
                In non diabetic pregnant mother, compensatory response occur such 
as beta cell hypertrophy and hyperplasia.   
 
 LIPOTOXICITY: 
           Besides the hyperglycemia, raised levels of free fatty acid is implicated in 
acquired defect in pancreatic beta cells and progression to diabetes from impaired 
glucose tolerance and its complication. 
 
 
  
 
 TUMOUR NECROSIS FACTOR α: 
                             TNF α is a cytokines produced by adipocytes, neutrophils, 
monocytes. fibroblast and macrophages. Increased level of this cytokine is 
associated with hyperinsulinemia.  
                              It impairs the insulin signaling by increasing serine 
phosphorylation  of  IRS-1 which in turn inhibits tyrosine  kinase  activity of 
insulin receptor.Catalano et al reported that 25% of increase in TNF α in 
association with body fat and insulin sensitivity changes. 
 
 LEPTIN: 
 
1. It is a polypeptide, secreted from adipocytes  and it is a OB gene. 
2. It inhibits food intake and decrease the body fat. 
3. It stimulates energy expenditure. 
4. It acts on hypothalamus to produce the above action. 
5. Possibly modulation of insulin sensitivity. 
 
 
 
  
                                            Hyperinsulinemia 
       
                                            Increased body fat (dyslipidemia) 
 
                                          Increased adipose tissue 
 
                                             Leptin level increases 
 
                                     Hypothalamus (increase appetite) 
 
                     Continuous feeding leads to weight gain mainly central obesity 
 
                  So hypothalamus mediated leptin resistance causes a rise in leptin and 
initiates hyperinsulinemia and insulin resistance in obesity. 
                 Highman et al(26) reported that in pregnancy the leptin level increased 
significantly before the physiological changes occur and also plasma level become 
normal after 24 hours of placental delivery. Leptin has a role in fetal growth and 
maternal carbohydrate metabolism. 
 
 
  
 THE INSULIN SIGNALING SYSTEM:  
                  Insulin receptor tyrosine kinase activity(27)is needed for signaling. It will 
be decreased in GDM patient more than the obese pregnant patient. 
 PROTEIN TYROSINE PHOSPHATASE: 
                 It regulates the phosphorylation and dephosphorylation reaction at 
cellular level. Some of the studies showed this enzyme modulates the insulin 
sensitivity and fuel metabolism. 
 
 INSULIN RECEPTOR SUBSTRATE PROTEIN: 
o The level of insulin receptor substrate protein and insulin mediated tyrosine 
phosphorylation are necessary for insulin sensitivity. 
o Decreased expression of IRS-1 in skeletal muscle of pregnant women 
o Increased IRS-2 level(27) which has the primary progesterone elements. So 
insulin resistance may be exerted by decreasing the signaling cascade at the 
level of IRS. 
 
 PHOSPHATIDYL INOSITOL 3 KINASE: 
                This protein activation is essential for glucose transport. This level will 
increase in both pregnant and GDM patients skeletal muscle. 
 
  
 GLUCOSE TRANSPORTERS: 
                 Insulin mediated glucose uptake is mediated by GLUT-4. In pregnant 
women, adipocytes has decreased expression of GLUT-4 leads to hyperglycemia. 
                Plasma glucose level between pregnant mother and their fetus is only 0.5 
mmol/l. Fetal glucose utilization rates (5-7 mg/kg/min) are higher than in adults (2-
3 mg/kg/min). 
The three key points in this complex regulation of fetal glucose metabolism(28) are:   
1. Maintenance of maternal glucose concentration by increasing maternal 
glucose production and development of relative maternal glucose intolerance 
and insulin resistance. 
2. Placental transfer of maternal glucose to the fetus, buffered by placental 
glucose utilization. 
3. Fetal insulin production and enhancement of glucose utilization in sensitive 
tissues 
 Oakley et al(29) reported that hyperglycemia induces facilitated diffusion across the 
placenta.  
                Fetal pancreas secretes the insulin as early as 10 to 12 weeks of 
gestation. In second trimester, fetal insulin level is elevated. Fetal pancreas is 
highly sensitive to maternal hyperglycemia.                     
  
              Beta cell dysfunction in women diagnosed with GDM may fall into 
autoimmune, monogenic or insulin resistance (common cause). 
 
 SECRETED PROTEIN ACIDIC AND RICH IN CYSTEINE  (SPARC): 
 
                              It is a newly identified adipokine, is a main regulator in the 
pathogenesis of obesity and T2DM. Recent studies determined circulating levels of 
SPARC in pregnant women and found that SPARC levels were increased 
significantly in GDM group of population compared with normal glucose tolerance 
test group of pregnant women and correlated significantly with insulin resistance. 
It is an independent indicator of insulin resistance. 
                       Levels of SPARC are significantly elevated in T2DM patients 
compared with normal controls in Chinese and Japanese populations. A recent 
study showed that human placenta villi(32) could express and secrete SPARC, 
suggesting that levels of SPARC may be affected by gestational age. SPARC may 
be connected to the inflammation and glucose intolerance by excessive synthesis of 
extra cellular matrix components.  
 
 
 
  
 
Proinflammatory environment 
 Up regulates expression of SPARC 
 
 
 
             
                                             
 
 
                                                    
 
                                                                                                     
                                                        
The co-existence of high SPARC level and increased inflammatory markers in 
GDM and their close relevance with each other and with insulin resistance suggest 
that their interaction may play an important role in the development and 
progression of GDM.  
 
 
 
       Adipose tissue fibrosis(30,31) 
            Insulin resistance 
           Synthesis of ECM components         
  
 
 FIBROBLAST GROWTH FACTOR 21 LEVEL:  
                       The levels of FGF21 in German GDM women assessed by Stein 
et al at mid-pregnancy (24–28th week of gestation) and showed that serum 
FGF21 levels(33) was not significantly different between patients with GDM and 
healthy pregnant controls.  
                      But another recent study done in UK in GDM women at end of 
third trimester of gestation reported that GDM women had significantly higher 
plasma levels of FGF21 than controls. The role of FGF21 in lipid metabolism 
and insulin resistance during pregnancy, need further study. 
 
 C- REACTIVE PROTEIN: 
                      Increased CRP levels and leukocyte count in the first trimester 
have been demonstrated to independently predict the subsequent development 
of GDM later in pregnancy. In one study, showed that circulating SPARC 
levels in the second trimester positively correlated with hsCRP levels, and with 
WBC count that were detected in the earlier trimester of pregnancy. Another 
previous study(34)  also expressed a strong correlation between serum hsCRP 
and SPARC expression in adipose tissue . 
 
  
 
 
PATHOGENESIS OF GESTATIONAL DIABETES MELLITUS:  
It is a heterogenous disorder. Multiple factor responsible for the pathogenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
High glycemic 
index 
Beta cell 
defects 
Genetic 
predisposition 
Increased insulin resistance 
Placental hormones 
GDM 
Insufficient 
insulin secretion 
Insulin resistance 
Increased adiposity 
Pregnancy 
Smoking 
Increase in 
inflammatory mediators 
Maternal age 
Beta cell 
defects 
Increased insulin resistance 
Increased adiposity 
Increase in 
inflammatory mediators 
  
EFFECTS OF PREGNANCY ON DIABETIC CONTROL: 
            Insulin resistance and resultant hyperglycemia and consequent enhanced 
lipolysis are of use in a non diabetic pregnant women as it enhances nutrient 
transfer to the growing fetus. 
            However in a diabetic women, this can be seen as a form of accelerated 
starvation and predisposes to ketosis. With growing fetus, the diaphragm is pushed 
upwards, resulting in a relative increase in alveolar ventilation with consequent 
respiratory alkalosis and compensatory renal tubular loss of bicarbonate. 
             A decrease in serum bicarbonate and loss of acid buffering capacity partly 
explains the occurrence of diabetic ketoacidosis in pregnancy with normal or mild 
to modest elevation of glucose. 
EFFECTS OF MATERNAL DIABETES ON THE PREGNANCY: 
Developmental malformation and altered islet cell development and accelerated 
growth. 
 Increased congenital anomalies 
 Increased risk of miscarriage and late uterine death 
 Pre-eclampsia 
 Macrosomia 
 Premature delivery and cesarean section rates 
 Perinatal mortality rates 
  
 
 anxiety to the patient  
 increased cost of care 
 The teratogenic effects of diabetes occur in the first 8 weeks of gestation, 
when the major organogenesis  occur. These abnormalities seen in the 
heart, musculoskeletal system and nervous systems. 
                    Congenital malformation can be related to the degree of 
hyperglycemia in early pregnancy and Hb A1c levels in the pre-pregnancy state. 
Enhanced delivery of glucose and other nutrients to the fetus results in accelerated 
fetal growth and macrosomia. This stimulates the islets and induces fetal 
hyperinsulinemia resulting in enhanced abdominal fat deposition, skeletal growth 
and organomegaly. 
 
COMPLICATION  ON THE NEONATE: 
Fetal life risk: 
 Intrauterine death 
 Macrosomia 
 Shoulder dystocia 
 Hypoxia ,acidosis 
 Nerve palsy 
  
 Prematurity and 
 Malformation 
 
Neonatal life: 
 Hypoglycemia 
 Hypocalcemia 
 Hypomagnesemia 
 Respiratory distress syndrome 
 Jaundice 
 Polycythemia 
 Cardiomyopathy. 
 
Adult life: 
 Obesity 
 Type 2 DM 
 Hypertension and cardio vascular disease. 
 
For every 18mg/dl increase in fasting glucose level incident of macrosomia 
doubles. 
  
 IN 1993-1995 DENMARK STUDY SHOWED THE OUTCOME AND 
MATERNAL EFFECT OF 1215 WOMEN WITH TYPE 1 DM IN 
PREGNANCY: Table-5: 
MATERNAL OUTCOME FOETAL AND NEWBORN OUTCOME 
Caesarian – 56% Respiratory distress syndrome -17% 
Pre-termed delivery -42% Neonatal jaundice -18% 
Pre-eclampsia -18% Congenital malformation -5% 
 Perinatal mortality -3% 
 Fetal macrosomia -63% 
                                                
 
SCREENING FOR GDM: 
                  Practically all pregnant women should undergo screening for glucose 
tolerance test. Screening test should be well defined, easily administered and 
reproducible and that should be significant sensitivity and some specificity. History 
is more important for early detection  of  case. 
INDICATION FOR SCREENING: 
HIGH RISK FOR GDM: 
I. Family history of diabetic 
II. Glucose in second fasting urine sample 
III. History of unexplained fetal loss 
  
IV. History of large for gestational age infant 
V. History of congenitally malformed infant 
VI. Maternal obesity. 
LOW RISK FOR GDM: 
I. Not known DM in first degree relatives 
II. No history of abnormal OGTT 
III. Age < 25 years 
IV. Normal weight women before conception 
V. Member of ethnic group with low prevalence population of GDM 
VI. No prior history of poor outcome obstetric history. 
 
• METHOD USED FOR SCREENING: 
 1.HISTORIC RISK FACTOR: 
O”sullvian and coworker(35) found that 53% of 19 GDM had the history of 
risk factors compare to 43% without GDM. History like age, family history of 
DM, previous large baby birth and other obstetric complication. Sacks and 
coworkers studied history with age >25, weight >150 pounds and other risk factor 
was showed 97% of sensitivity for gestational diabetic. But it is difficult in case of 
first pregnancy. history and clinical risk factor have low sensitivity compare to 
other screening test. 
  
 
 2.SIMPLEST SCREENING PROCEDURE  : 
             It is detection of glucose in the urine. Low sensitivity and high specificity. 
It is not a good screening because renal glycosuria common in pregnancy. 
Lactosuria in 3rd trimester also give the positive results. Screening test can be 
accepted by demonstrating  glycouria in the second fasted urine sample. 
 
 3.RANDOM BLOOD GLUCOSE LEVEL:  
             Simple and easy to perform. Strangenberg et al(36)  studies 1500 patients 
capillary blood sample without GDM. Identification rate was o.7%. Another study 
in kuwait, done with 276 patients without GDM. After the random blood glucose 
level, 250 patients under went GTT for conformation.3 had GDM and 46 patients 
had impaired glucose tolerance. So this test had insufficient screening test. 
 
 4.FASTING GLUCOSE AND POSTPRANDIAL GLUCOSE LEVEL; 
               FBS is > 95mg/dl needed further diagnostic test. Sacks et al and daniele 
et al reported that 70% of the women did not need the diagnostic test and 19% of 
cases were missed.2 step approach used for diagnosis and preferable to challenge 
test. 
 
  
 
 5.ADA  RECOMMENDS  2  STEP  APPROACHS; 
 
    A . One step approach(37);  Diagnostic method and doing oral glucose tolerance 
test without previous plasma glucose screening. 
C. Two step approach: Initially by doing glucose challenge test (GCT) and 
followed by perform a diagnostic oral glucose tolerance test(38) (OGTT) 
 
 GCT:  Done by measuring the plasma glucose one hour after 50 grams of 
glucose. It has positive predictive value. 
If the GCT more than 140 mg/dl, then go to OGTT with 100 gm of glucose. 
 
 O’sullivan and Mohan criteria: Table-6: 
TIME(hour) 100g OGTT(mg/dl) 
Fasting 90  
One hr 165 
Two hrs 145 
Three hrs 125 
 
 
  
 National and Diabetic data group: Table-7: 
TIME(hour) 100g OGTT(mg/dl) 
Fasting 105  
One hr 195 
Two hrs 165 
Three hrs 145 
 
 100 g glucose load (O’sullivan and Mohan criteria modified by Carpenter 
and Causen)- Table-8: 
TIME(hour) 100g OGTT(mg/dl) 
100g 
OGTT(mmol/l) 
Fasting 95  5.3 
One hr 180 10 
Two hrs 155 8.6 
Three hrs 140 7.8 
 
 BY USING 75 GMS OF GLUCOSE: Table-9: 
TIME (hour) 75g OGTT(mg/dl) 
75g 
OGTT(mmol/l) 
Fasting 95  5.3 
One hr 180 10 
Two hrs 155 8.6 
  
 
Drawback of  ADA guideline is same cutoff value with different glucose load, but 
in USA used this method. Other countries follow the WHO guide line. Schmidt et 
al found that prevalence of GDM was 2.4% with ADA criteria but 7.2% with 
WHO criteria in a pregnant population. 
 4th international workshop on GDM and European association for study of 
DM concluded the following values with one with 75 gm and another study 
with 100 gm of glucose. Table-10: 
4 TH INTERNATIONAL 
WORKSHOP ON GDM 
EUROPEAN ASSOCIATION 
FOR STUDY OF DM 
75 gm OGTT dose(mg/dl) 100 gm OGTT dose(mg/dl) 
Fasting 95  Fasting 95  
Two hrs 155  Two hrs 162 
 
IADPSG:  International association of diabetes and pregnancy study groups and 
DIPSI (39):   Diabetes in pregnancy study group india , values are -Table-11: 
                       IADPSG (mg/dl)                            DIPSI  (mg/dl) 
Fasting plasma glucose >92 mg/dl              _ 
1 hour post glucose >180 mg/dl              _ 
2 hour  post glucose >153 mg/dl Two hour  post glucose >140 mg/dl 
  
 
Disadvantages  of  OGTT:  
o Non – reproducibility ,  
o Time taken for test. 
 
 6.WHO CRITERIA:   It is simple and cost effective.  
 WHO criteria---FPG ≥ 6.1 mmol/l and 2 Hour PPG is ≥ 7,8 mmol/l. WHO 
CRITERIA FOR 75 G OGTT : Table-12: 
TIME IMPAIRED GLUCOSE TOLERANCE(mg/dl) DIABETIC(mg/dl) 
Fasting < 126  140—200  
Two hrs ≥ 140 -199  >200  
 
                   Pregnant women classified as GDM, who either meet IGT or Diabetes 
criteria. Impaired glucose tolerance and impaired fasting glucose are a stage before 
development of frank diabetes, when higher than normal values of blood glucose 
are observed.           
 7.GLYCOSYLATED HB A1C: 
                      Glucose tolerance during pregnancy only brief period of time before 
testing. In early pregnancy, erythropoiesis increased so new Hb which has not 
reached sufficient glycosylation. 
  
 
 8.FRUCTOSAMINE ASSAY: 
          Fructosamine is associated with glycemic control over 1 to 3 weeks. 
Hoffman demonstrated fetal hyperinsulinemia associated with fructosamine 
>2.6mm in women with GDM. it is used for fetal screening not for routine GDM 
screening test. 
 
 9. INTRAVENOUS GLUCOSE TOLARENCE TEST: 
 Indication:  
 It can be done in those with abnormal intestinal absoption.  
 In pregnant women who do not tolerate the glucose tolerance test. 
 
                   25 gms of glucose in 50% solution give IV over 3 min. samples 
collected every 10 mins for 1 hour and a graph of blood glucose against time 
plotted. The rate constant is calculated by a formula K = o.693 × 100 /1.5. 
Normally K is 0.9 to 2.3, if K is below 0.9, it indicates diabetes. 
Advantage: is shorter procedure and eliminates irregular oral absorption. 
Disadvantage: is frequent blood collection. 
 
 
  
MANAGEMENT : 
Medical therapy:  
Nutritional supplementation is main for GDM management. All patient with GDM 
should receive nutritional counseling. Treatment  should be planned to achieve 
glycemic goals without weight loss or undue weight gain. 
 Divide their caloric consumption, especially the breakfast atleast 2 hour 
interval to avoid undue peak of plasma glucose level. 
 Dietary components in pregnant women: 
 Calories  in 1st trimester—30 to 32 Kcal/kg  IBW  and  
 II , III trimester -38 Kcal/kg  IBW 
 Carbohydrates---50-55% of calories (not < 200 gm)  
 Fats--< 30 % of calories. 
 Protein—1.5 – 2.0 gm/kg  IBW 
 Fiber –20-40 g/day. 
Fasting level should be maintained with 3.3 to 5.0 mmol/L  and postprandial 
glucose level at 1 hour should be maintained with < 7.8 mmol/l. 
 INSULIN: 
If the nutrient therapy fail to achieve glycemic control by 2 weeks, insulin therapy 
should be started.  
 
  
Indication for insulin therapy:  
According to American diabetes association (ADA) is 
1. Fasting plasma glucose >105 mg/dl 
2. One hour post glucose  >155 mg/dl, 
3. Two hour post glucose  >130  mg/dl, 
                    NPH insulin can be started with low dose of 4 units and adjusted 
during follow up. Or combination of 2/3 rd of intermediate acting with 1/3 rd of 
short acting before breakfast. 
 
INSULIN ANALOGS IN PREGNANCY(40):  
                    One complication of insulin therapy during pregnancy is insulin 
antibodies. Compare to regular insulin, the rapid acting insulin analogs are useful 
in GDM, as they are able to reduce postprandial hyperglycemia more efficiently.  
Lispro and Aspart and Glulisine are assigned in the pregnancy category “B”. 
• Demonstrated clinically more  effectiveness 
• No evidence of teratogenesis. 
• Low antigenicity. 
                    Long acting insulin like glargine are contraindicated in pregnancy as 
there is insulin like growth factor receptor affinity and mitogenic potency.  
 
  
 
                  Insulin glargine and insulin detemer are considered category “C” by 
food and drug administration. 
 
MANAGEMENT OF DIABETIC DURING LABOUR: 
• Elective  delivery  and  induction  of  labour  at 38 to 39 weeks in poorly 
controlled  blood sugar. 
• CESAREAN SECTION:  needed in case of  
1. Fetal weight is > 4.5 kg 
2. Malpresentation 
3. Disproportion 
4. Pre-eclampia 
5. History of previous still birth 
6. Poor maternal compliance 
• During labour, blood sugar should be maintained between 72 mg/dl -
126mg/dl with regular insulin. Monitor blood glucose level every  1-2 hours. 
• Following delivery, insulin requirement is sharply falls, so insulin should be 
reduced 25-40% of the pre-delivery dose to prevent hypoglycemia. 
 
 
  
 
MANAGEMENT  OF  DIABETES  DURING  POSTPARTUM  PERIOD: 
• GDM patients should be reassessed at 6-12 weeks postpartum. 
• The ADA recommends screening at 6-12 weeks of postpartum with a 
seventy five grams of oral glucose tolerance test. 
• After delivery who have normal glucose level should be evaluated at least 
every 3 years or subsequent pregnancy. 
• NATURAL COURSE OF GDM AFTER PREGNANCY: 
 
HOMOCYSTEINE: 
                     Butz  and du vigneud(41)  was coined the word Homocysteine  and 
homocystine   70 years ago  at Illinosis  university.  
• It is a non-protein forming sulfur amino acid . 
GDM
REVERT TO NORMAL 
GLUCOSE TOLERANCE 
80%
IMPAIRED GLUCOSE 
TOLERANCE 
20%(POSTPARTUM 
PHASE)
LIFE TIME RISK OF 
T2DM >50%
  
• Metabolism of homocystine is interaction between the  metabolic 
pathways of two reactions namely remethylation and trans-
sulfuration respectively. 
•   The sulfur has an atomic weight of 32,064 and atomic number of 
16. In 1977, Antoine Lavoisier indentified this element. 
• “THIOL” refers to compounds containing sulfur of both the 
reduced (sulfhydryl) and oxidized (disulfide) forms.   
                          An  abnormality of this homocysteine metabolism explained by 
Carson and Naill in 1962. They were first identified from Northern Ireland siblings 
as a cause of mental retardation. In these patient vascular pathology such as 
smooth muscle proliferation, progressive stenosis of artery, and haemostatic 
changes. 
                         In last 20 years, lot of studies documented that moderate 
hyperhomocysteinemia is a harmful factor for arterial occlusive disease and 
thrombosis of veins. More than 50 percent of the cerebrovascular accident, chronic 
kidney disease and diabetes mellitus have the moderate rise in this level. 
                 In pregnancy this homocysteine have the lot of complication in both 
mother and the fetus such as placental vasculopathy, congenital abnormalities –
cleft lip, cleft palate and cardiac abnormalities, and spontaneous abortion when 
compare to control groups. 
  
                  In some studies found that an association between increasing 
homocysteine level and cognitive impairment. And also an association with 
depression and other neuropsychiatric disorders was found. The recent 
identification of polymorphism of gene involving in homocysteine metabolism and 
there decreased enzyme activity has lent the research. 
Formula  of  homocysteine  is  HSCH2CH2CH(NH2)CO2H.  It  is same like 
cysteine  but  it has extra methylene (-CH2-) groups. 
 
 STRUCTURE:-   
                                            NH3+ 
  
CH3  -  S  -  CH2  -  CH2  -   CH                                   
                   
                                           COO -- 
 METHIONINE: 
  
                            O 
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CH3   OH 
 NH2 
 
 
 
  
 
 
 
 
 Protein bound homocysteine (70-80%) 
 
 
                                                             NH3+ 
       
                 -  S  -  S  -  CH2  -  CH2  -   CH   
 
                                                            COO- 
 
 Reduced form:- 
 
                                           NH3+ 
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                                            COO 
 Mixed disulphide form: 
         NH2                                                        NH2 
 
CH – CH2 – CH2 – S – S – CH2 –CH2 – CH 
 
        COOH  COOH 
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 Albumin (protein)-homocysteine mixed disulphide: 
                                                                                     NH2 
                                     
 – S – S – CH2 –CH2 – CH
       
                                                                                        COOH     
         
METABOLISM OF HOMOCYSTEINE(42,43): 
3 steps are there. 
• Demethylation 
• Transmethylation 
• Transulphuration. 
1. DEMETHYLATION; 
Methionine is an one of the 9 essential amino acid. Human cannot synthesis it must 
be supplied by the diet, Methionine. 
 
 
 
 
                      Methyl transferase 
  (Vit B12,folic acid) 
 
 Diet containing methionine        
(meat,eggs,milk) 
       homocysteine 
ALBUMIN 
  
 
 
 Methionine                  S- adenosyl methionine              S-adenosyl                                                                                                                     
                                                                                                   homocysteine 
 
                                                                                                         homocysteine 
 
 
             Methionine  first  converts  into S-adenosyl methionine  and become                                                                                                                     
S-adenosyl homocysteine (SAH).  SAH undergo the hydrolysis  reaction  to  
produce  homocysteine  and  adenosine. Depending  on  the  level of the 
methionine, homocysteine  enter either transmethylation or transulphuration. 
 
2.TRANSULPHURATION: 
             This pathway convert the homocysteine which condense with serine 
molecules to form cystathione which is not a reversible reaction. In the 
presence of cystathione beta synthetase and cystathione is hydrolysed by 
gamma cystathionase into cysteine and alpha keto butyrate. Both are vitamin 
B6 dependent enzyme (pyridoxal -5-phosphate). 
 
  
                         Cystathione β synthetase & B6  
 
Cysteine  either excreted into urine or in-cooperated  with glutathione.
 
 
 
3.TRANSMETHYLATION: 
             In this reaction, homocysteine acquires a methyl group from the N-5- 
methyl tetrahydro folate (MTHF) or from betaine (trimetyl glycine) to form 
methionine. In our body, MTHF reaction occur in all tissues and it is vitamin B12 
dependent process where as the reaction with betaine occurs mainly in liver  and it 
is not vitamin B12 dependent. 
homocysteine+serine cystathione cysteine
CYSTEINE
SULPHATE+H2O
URINE
  
 B12dependent pathway: 
                                   
 
                    Methionine synthase                                    5 Methyl THF 
                                       B12                                   THF 
 
                                       
B12 independent pathway: 
                             Betaine homocysteine methyl transferase 
       Homocysteine                  methionine 
                                     Betaine         BMG 
 
               
                 Metabolic abnormality of any of these reaction leads to 
accumulation of homocysteine and it produces lot of complications. So 
sulphuration reaction catabolizes excess homocysteine and delivers sulfate to 
synthesis of heparin, heparin sulfate, chondroitin sulphate and dermatine 
sulphate, because of the existence of a homocysteine catabolism plasma 
contain only a very small amount of homocysteine. 
   homocysteine 
      methionine 
  
 
                  Total homocysteine is the sum of protein bound and free 
homocysteine. 80% of total homocysteine in circulation is bound to protein 
by disulphide bonds. In plasma rapidly it become oxidized and mostly 
present as a mixed disulfide with albumin, and small amount of free 
circulating disulfide forms. 
                    S-adenosyl methionine provide methyl group to multiple 
reaction including methylation of DNA, RNA, proteins, phospholipids and 
myelin. So defect in methylation leads to defect in cellular growth, 
differentiation and function.  
                    Neurochemical processes are delayed as in ageing, depression, 
and neuropsychiatric disorders. Congenital abnormality carcinoma due to 
DNA repair problems. Demyelination in severe inborn error metabolism due 
to lack of synthesis of methyl groups.                   
                  Glutathione which is an important endogenous antioxidants 
properties, and synthesis depends on the homocysteine transulphuration 
reaction. It helps to protect cellular component against vascular damage. It 
also have the possible vascular productive effect by interaction with nitric 
oxide. 
 
  
HYPERHOMOCYSTEINEMIA: 
Kang et al(44) described the abnormal homocysteine in normal 
individual. In healthy individual, fasting homocysteine level < 15 
micromol/l. kang and coworkers, classify it into mild, moderate and severe 
according to the level.       Table-13: 
MILD 15 -3O µmol/l 
MODERATE 30-100 µmol/l 
SEVERE >1OO µmol/l 
 
 
FACTORS RESPONSIBLE ELEVATED SERUM HOMOCYSTEINE 
LEVEL: 
• Inherited cause. 
• Acquired cause 
PRIMARY HYPERHOMOCYSTEINEMIA : 
                 It is due to inherited causes. Genetic defect in genes encoding 
enzymes involved in homocysteine metabolism or depletion of important co-
factors or co-substances for those enzymes, including vitamin B12, folate, 
  
and vitamin B6 may results in elevated homocysteine level in plasma. 
3 types of homocysturia : Depending upon the enzymes involvement, type 
I, II, and III. 
 Cystathionine beta synthase deficiency: 
Commonest type of all three, and inherited as AR (autosomal recessive).It is 
mainly characterized by mental retardation, downward dislocation of eyes 
(ectopic lentis), marfanoid features  and premature atherosclerosis. 
In these individuals, fasting plasma homocysteine concentrations can be as 
high as 400 micromol/l.  
Several CBS mutations are known at present, the most frequent are 833TC, 
and 919GA located in exon 8 and 1224-2AC which causes the entire exon 
12 being deleted. 833TC is spread in several ethnic groups.  
The 919GA mutation has been almost exclusively reported in patients of 
celtic region. There are several novel mutation s indentified such as 146 CT, 
172CT, 262CT, 346GA, 374GA, 376AG,869CT, and 904GA. 
 5,10 methylene tetra hydro folate reductase deficiency: 
Abnormal in gene in chromosome 1 implicated as a cause of  MTHFR 
reduction. More  prevalence in Mediterranean region and 12% prevalence in 
Europeans. The thermolabile form of the enzyme MTHFR is a genetic 
  
abnormality that occurs in 4% to 10% of the general population as a 
homozygous form. 
 C677T gene point Mutation  leads to elevated homocysteine and low 
plasma folate level. It is commonly due to alanine-valine substitution. 
Person with homozygous mutation to have hyperhomocystenemic response 
with depletion of folic acid which leads to increased cardiovascular risk. 
And also A1298C mutation in MTHFR gene  also indentified. 
It have a worse prognosis than cystathionine-3- synthase deficiency, due to 
complete lack of effective therapy. 
 Methylene tetra hydro folate homocysteine methyl transferase 
deficiency. 
ACQUIRED CAUSES:    
Secondary  hyperhomocystenemia  due  to either physiological or secondary to 
organ dysfunctions. 
 Physiologically elevated level seen in  
 Elder person ( due to malabsorption of vitamins and amino acids), 
 Male gender, 
 Post menopausal women and coffee intake. 
 
  
 Dietary deficiency of vitamins such as vitamin B12, B6 and folate.  
 Smoking interfere with synthesis  of  pyridol phosphate .  
 Tobacco also influence the homocysteine level. 
Disorder associated with elevated level, systemic disorder such as  
 Chronic renal disorders 
 Chronic liver diseases 
 Coronary artery disease 
 Pernicious anemia –intrinsic factor deficiency. 
 Alzhemier disease 
 Diabetes mellitus 
 Systemic lupus erythematosus 
 Hypothyroidism – A number of studies suggesting a potential mechanism 
for vascular disease in hypothyroidism. 
 Organ transplantation ( cardiac and kidney ) 
 Drugs,   
 Malignancy such as ovarian, breast and pancreatic cancer. ALL also 
associated with elevation, after chemotherapy for this disorder, it will be 
reduced.  
 
 
  
                    Hyperhomocysteinemia has been reported in :Table-14: 
                 
            Western people 
                            
 11-22% 
            
      Chinese in Hong Kong 
 23-36%( premature coronary artery disease ) 
29% (nonselective series of coronary subjects) 
. 
Severe hyperhomocysteinemia is very rarely seen, but mild increase can occur in 5 
to 7 % of general population. Further studies reveal that the prevalence estimates 
of hyperhomocysteinemia vary between 5% -30% in the general population. 
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AGE AND GENDER: 
           In both male and female plasma homocysteine level increases with 
increasing age. This may be due to differences intake of diet like vitamins 
and aminoacids in various age of people. Pre pubertal stage both gender have 
the same value. During puberty it is increasing but girls have lower value 
than boys.  The gender disparity may be due to muscle mass, hormonal status 
and life style differences.  
                Postmenopausal women have elevated homocysteine level 
compare to menstruating women. Premenopausal women have decreased 
homocysteine level when compare to male. This may be cause of sex 
hormones.  
In elderly patients, higher level of homocysteine due to   
 Malabsorption food due to atrophic gastritis 
 Inadequate nutritional intake 
 Inadequate supplies of vitamins 
 Reduced metabolism 
 Lower kidney functions 
 
  
 
NUTRITIONAL FACTORS: 
          Vegetarian diet containing very low amount of vitamins such as B6, 
B12.  So vegetarian diet(45) patients, found with elevated level of 
homocysteine. 
LIFE STYLE:   
It determines the level of homocysteine.   
• Lower level seen in patient with moderate amount intake of alcohol 
and normal physical activity(46).. 
• Higher level seen in excess alcohol intake, caffeine and smoking. 
• Lack of physical activity, obesity and even stress leads to hyper 
homocysteinemia. 
• In alcoholic person, may be due to vitamin deficiency or excess 
alcohol affects the one carbon metabolism. 
PREGNANCY:  
During pregnancy its level will be reduced owing to    
 Increased plasma volume, or  
 Increased metabolic rate and  
 Glomerular filtration rate. 
  
 
LIVER DISEASE:  
Synthesis and metabolism of homocysteine take place in the liver. So it has 
important role. In chronic liver disorder(47)its level elevated. It is mainly by  
           1. Decreased and utilization of B-complex vitamins 
           2. Gene expression defect which is involved in its metabolisms. 
    Turkish researches evaluated, they found that homocysteine were 
significantly elevated in non alcoholic fatty liver disease. They published in 
a September 2005 edition of gastroenterology and hepatology. 
 
RENAI DISEASE(48): Elevated homocysteine in CKD are independent risk 
factor for coronary heart disease. Elevated level in chronic kidney disease 
due to 
 Reduced systemic clearance     
 Enzyme inhibition 
 Presence of MTHFR thermolabile polymorphism 
 Absolute or relative deficiency of folate  
 Reduced folate absorption 
 Enhanced folate excretion in haemodialysis patients 
 
  
ORGAN TRANSPLANTATION:  
                        Approximately 54 – 87 % of orthotopic heart transplant recipients 
develop hyperhomocysteinemia, which emerge after three months of transplant.  In 
kidney transplantation as many as 29 % of patients having elevated level 
depending upon the folate level and degree of renal impairments. The changes in 
homocysteine level after renal transplantation, reported by In 1981 Wilcken et 
al(49). Immunosuppression used in after transplant also important implication. 
Another study  done  by Massy et al and also Bostom et al(50)explained the 
increased prevalence of hyperhomocysteinemia in post renal transplant patients 
compared to control group. 
HOMOCYSTEINE IN MALIGNANCY: 
Methionine –dependent malignant cells in organs of lung, kidney, breast, 
bladder and colon cannot convert the homocysteine to Methionine. It results in 
homocysteine accumulations. So in lung cancer it can be used in early cancer 
biomarker. DNA methylation plays a role in gene regulation for control of normal 
growth of cell, differentiation and apoptosis. Microarray- based studies explained 
that hypomethylation contribute to cancer initiation and progression. its level also 
increased in ovarian, pancreatic, colorectal , head and neck squamous cell 
carcinomas. 
 
  
DRUGS: Many drugs influence the Plasma homocysteine level. 
The following drugs elevates the homocysteine level: 
 Immunosuppressive methotrexate which is folate antagonist, 
  Anti epileptic such as phenytoin and carbomazepine. 
  Theophylline, PDE inhibitor which antagonizing the synthesis  of  pyridol 
phosphate . 
 Cholesterol lowering drugs(51)like cholestyramine, colestipol interferes with 
absorption of vitamin B12 and folic acid. 
 Metformin which is used in the treatment of diabetes decreases the 
absorption of cobalamin and increases the serum homocysteine level. 
 Bezafibrate and fenofibrate alters renal function so increases the serum 
homocysteine level. 
 Nitrous oxide increase serum homocysteine by causing impairment of the 
enzyme methionine synthase. 
 Levodopa used in the treatment of Parkinson disease increases the serum 
homocysteine level by increasing the formation of S-adenosyl 
homocysteine. 
 Niacin and theophylline causes vitamin B6 deficiency and hence increases 
homocysteine level. 
 
  
SOME OF THE DRUGS LOWER THE HOMOCYSTEINE LEVEL: 
 Penicillamine, Acetylcysteine  are interferes with disulphide exchange 
reactions. 
 Oestrogen(52)  containing oral contraceptives may have a beneficial effect on 
plasma homocysteine level. 
 Tamoxifen is  the  drug used in the treatment of breast cancer also showed to 
reduce plasma homocysteine level. 
 Betaine increases vitamin B12 independent remethylation of homocysteine 
thereby reducing  its level in plasma. 
 
COMPLICATIONS OF HYPERHOMOCYSTEINEMIA:- 
 Coronary artery disease 
 Ischemic heart disease 
 Venous thromboembolism 
 Peripheral vascular disorder 
 Hypertension 
 Diabetes vascular complication 
 Osteoporosis 
 Dementia and alzhemier disease 
 In eye, central retinal artery occlusions  and 
  
 In pregnancy complications ,such as 
• Recurrent fetal loss, 
• Intra uterine death 
• Thrombo-embolic disease in pregnancy 
• Neural tube defect, 
• Congenital cardiac complication 
• Pre-eclampsia, 
• Placental abruption 
•  Intra uterine growth retardation. 
In pregnancy complications: 
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HOMOCYSTEINE AND DIABETES MELLITUS: 
                   Moderate elevation of plasma homocysteine level was observed in 
lot of studies in diabetic patients(53). Plasma homocysteine level in adolescent DM 
patient without vascular complication had similar level when compare to non 
diabetic control group. The homocysteine levels were not dependent of vitamin 
status and it reflect the various factor of the patients, including patients with poor 
glucose control, longer duration of diabetes and its complications. 
DETERMINANTS :   
 Genetic factors :  
                  The most common genetic cause is the C677T mutation of the 
methylenetetrahydrofolate reductase (MTHFR) gene. The prevalence of this 
mutation among different ethnic groups with a prevalence of 0–2% in 
Africans,12% in Whites and 20% in Asians. A recent meta-analysis has shown 
a significantly higher risk of ischemic heart disease in people with the MTHFR 
mutation  
                   In a study of 354 patients with type 1 diabetes, the C677T mutation 
has no significant changes in plasma homocysteine levels. Although the 
MTHFR polymorphism has been observed more frequently in patients with 
diabetes with nephropathy compared with those without nephropathy. 
  
 
                            The incidence of heterozygotes for cystathione beta-synthase 
deficiency in the general population is less than 1% and has not been studied in 
diabetes. 
 NUTRITION:  
 
 Folate and vitamin B12 deficiency lead to reduced remethylation of 
homocysteine to methionine and  increased plasma homocysteine levels . In 
most studies of plasma homocysteine levels in diabetes, serum B12 and folate 
levels was within the normal range. 
 Riboflavin (vitamin B2) is a co-factor for MTHFR and deficiency of riboflavin 
associated with increased plasma homocysteine levels, particularly in patient 
with low folate status and the MTHFR C677T mutation. 
 vitamin B6 deficiency, the trans-sulphuration pathway is only mildly impaired 
and most studies have found that in vitamin B6 deficiency , elevation of 
homocysteine after oral methionine loading. There is no evidence of riboflavin 
or vitamin B6 deficiency in patients with diabetes. Nutritional deficiencies may 
lead to mild hyperhomocysteinaemia are more common in elderly patients and 
strict vegetarians. 
  
 CORONARY ARTERY DISEASE AND HOMOCYSTEINE: 
 ENDOTHELIALDYSFUNCTIONBYHOMOCYSTEINE:                                                                                        
Endothelium necessary in maintaining vascular tone and the endothelial 
permeability. Nitric oxide (NO) is the prime regulator for the vascular tone.  
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                          Its role in coagulation cascade through thrombomodulin- protein C 
and heparin  sulphate  and  anti thrombin III interactions. Fibrinolytic functions of  
the Endothelium  which are mediated through plasminogen activator inhibitor -1, 
tissue  plasminogen activator (t-PA). another action influenced by endothelial cells 
is the sub-endothelial matrix composition and smooth muscle cell proliferation. 
Homocysteine causes disruption of endothelial layer and changes it character to 
pro-coagulant form from anti-coagulant properties. 
 
 It causes direct injury to endothelial cells by generating free oxygen radicals. 
So promotes the vascular endothelial injuries. 
 It Impairs the endothelium-dependent relaxation. Homocysteine impairs 
the vasodilation mediated by endothelial cells. This endothelium dependent 
vasodilation is due to production of nitric oxide (NO).  
 In the presence of increased homocysteine levels, nitric oxide is decreased 
and thereby affecting endothelium dependent vasodilation . Homocysteine  
promotes lipid peroxidation, that in turn decreases the expression of NO 
synthase enzyme in endothelial cells. It also increases the degradation of 
NO. 
 
  
 
  Alters the coagulant properties of blood. 
  HCY undergoes auto oxidation to form homocysteine mixed disulphides 
and homocysteine thiolactate. During this auto oxidation, superoxide anion, 
hydrogen peroxide, hydroxyl radicals are produced. These free radicals 
causes vascular injury.                    
      Superoxide radicals  causes oxidation of low density lipoprotein. High serum 
levels of homocysteine also increase reduced homocysteine  level inside the cells. 
It leads to reduces intracellular glutathione and NAD+ and alters the ratio between 
the reduced glutathione and oxidized glutathione. 
 Homocysteine  help to enhance the expression of monocyte chemoattractant 
protein -1(MCP-1) in endothelial cells. This MCP-1 increases the 
transmigration of monocytes from sub-endothelial matrix and promotes 
atherosclerosis. 
 Homocysteine increases the proliferation of smooth muscles present in sub-
endothelial matrix. In an animal experimental study conducted in rat showed 
that aortic smooth muscle cells, increased DNA synthesis were noted after 
exposure to homocysteine. During this  studies, increased cyclin D1 and 
cyclin A mRNA levels also were noted.  It increases collagen deposition in 
the  atherosclerotic  plaque. 
  
 
Homocysteine and hypertension(54): 
                         Vascular risk associated with elevated Homocysteine observed in 
hypertensive individual, because of the positive correlation of homocysteine with 
hypertension. Now a days most of the studies has been focused on the relations 
between plasma homocysteine and blood pressure. 
                The observational study of the third National Health and Nutrition 
Examination Survey (NHANES III), persons in the highest quintile of plasma 
homocysteine had a 2- to 3-fold increased prevalence of hypertension relative to 
those in the lowest quintile. Role for homocysteine in the pathogenesis of elevated 
blood pressure is explained by the demonstration that homocysteine-lowering 
treatment is associated with a reduction in systolic and diastolic blood pressures. 
 
A role for plasma homocysteine in the pathogenesis of hypertension: 
• Increased arterial stiffness 
• Impaired endothelial integrity 
• Reduced vasodilatory capacity 
• Insulin resistance 
                        
                            
  
 
 
                 Study conducted in Srilanka, by  Mendis S and et al identified the 
association between hypertension and homocysteine level. They concluded  that  
serum homocysteine level was significantly higher in patients with hypertension. 
Also Bortolotto LA et al demonstrated that increased homocysteine levels in 
hypertensive patients  was  associated with increased arterial stiffness. 
 
HOMOCYSTEINE AND CEREBRO VASCULAR DISEASE: 
                 A elevated homocysteine level is associated with a higher risk of 
strokes. Carotid stenosis appears to role in response to increased levels of 
homocysteine. Increased carotid plaque thickness often associated with high 
homocysteine and also low B12 levels. 
                Yoo et al studied  in both intracranial and extracranial vessels by MR 
angiography and reported that homocysteine levels was higher in patients with 2- 
or 3-vessel stenosis than in those with 1-vessel stenosis.  
                 Boushey et al (55) done a meta-analysis including many studies regarding 
the association between the homocysteine and cerebrovascular disease. Out of that 
9 studies showed that increased homocysteine were an independent risk factor for 
stroke.             
  
                           In a prospective study conducted from Netherlands, positive 
association between hyperhomocysteinemia and stroke was demonstrated. Also 
graded linear association between homocysteine and risk of stroke has been 
observed in the prospective study, British Heart study.  
 
LIST OF STUDIES : Regarding the association between homocysteine and 
cardiovascular disease, peripheral vascular disease, stroke; 
This showed study conducted in the year of 1992 and 1994.: Table-15: 
 
Year ,Author Population Endpoint of 
study 
Follow-up 
(years) Co-relation 
In 1992 
Stampfer et 
al 
 
U.S physicians MI / death 5 years Positive 
In 1994 
Alfhan et al 
 
Community MI 9years Negative 
In 1994 
Verhoef et al 
 
U.S physicians Stroke 5years Negative 
 
 
 
 
  
Studies from 1995 to 1996: Table-16: 
Year ,Author Population Endpoint of 
study 
Follow-up 
(years) Co-relation 
In 1995 
Perry et al 
 
Community Stroke 13 Positive 
In 1995 
Arnesan et al 
 
Community MI 3-4 Positive 
In 1996 Petri 
et al 
 
SLE patients Stroke/ CVD 4.8 Positive 
In 1996 
Chasan taber 
et al, 
U.S 
physicians MI /death 7.5 Negative 
 
 
Studies from 1997 to 1999: Table-17: 
Year ,Author Population Endpoint of study Follow-up (years) Co-relation 
In 1997 
Ridker et al 
 
U.S 
physicians DVT 10 Positive 
In 1997 
Evans et al 
 
Community MI /death 20 Negative 
In 1997 
Verhoer et al 
 
U.S 
physicians Angina/CABG 9 Negative 
  
In 1998 
Folsom et al 
 
Community CAD /death 3.3 Negative 
In 1998 
Moustapha   
et al, 
ESRD CVD /death 1.5 Positive 
In 1999 
Taylor et al 
 
PVD CVD /death 3 Positive 
In 1999 Bots 
et al 
 
Community Stroke /MI 4 Positive 
In 1999 
Bostom et al 
 
Framingham 
cohort CVD / death 10 Positive 
In 1999 
Nahlawi et al 
 
Heart 
transplant 
patients 
CVD / death 2.4 Negative 
 
 
HOMOCYSTEINE AND PERIPHERAL VASCULAR DISEASE(56): 
              A study by Clarke et al, Hyperhomocysteinemia was observed  
a) In 7 of 25 with peripheral vascular disease (in 28% of patients with PVD), 
b) In 16 of 38 patients with cerebrovascular disease (42% of patients with 
cerebrovascular disease) and  
c) In 18 of 60 with coronary vascular disease (30% of patients with CAD). 
                   In the present issue of Circulation Research, Chang et al  showed that a 
specific homocysteine-induced down regulation of fibroblast growth factor (FGF)2  
  
 
involved in the disruption of endothelial integrity by both reducing endothelial cell 
proliferation and inducing endothelial cell apoptosis. Recently, new studies 
providing insight into the regulatory effects of elevated homocysteine levels are 
necessary for the development of new diagnostic and therapeutic research. 
                     At the molecular level studies proposed several potential mechanisms:  
including  
• Induction of endoplasmic reticulum stress  
•  Unfolded protein response (UPR),  
• Protein N-homocysteinylation, and  
• Epigenetic effects concerning methylation status 
And also homocysteine reduces the expression levels of endothelin-1, a well-
known potent vasoconstrictor.  
 
                      The recent observational studies showed that hyperhomocysteinemia 
inhibits reverse cholesterol transport by reducing circulating  HDL via inhibiting 
the antioxidant apolipoprotein A-I protein synthesis and increasing HDL 
cholesterol clearance seems special relevant. 
 
 
  
 
HOMOCYSTEINE AND VENOUS THROMBOSIS: 
                        In many of the studies found that increased homocysteine level is an 
independent risk factor for venous thromboembolism.  Approximately 25 
retrospective studies, two recent prospective studies have demonstrated that 
hyperhomocysteinemia is an independent risk factor for premature arteriosclerotic 
disease in the coronary, cerebral, and peripheral arteries. 
                     Brattström et al found that no significant difference in plasma 
homocysteine concentrations between 42 patients with VTE and healthy control 
subjects. Bienvenu et al  reported that 7 of 23 patients with VTE was significantly 
increased (>2 SD) homocysteine levels and concluded that hyperhomocysteinemia 
is a risk factor for venous and arterial thromboses.                
                           Den Heijer and et al(57) demonstrated high levels of serum 
homocysteine with recurrent venous thrombosis  patients. They estimated 
homocysteine level in patients with age less than 70 years with first episode of 
deep vein thrombosis and concluded that mild hyperhomocysteinemia is a risk 
factor for deep vein thrombosis. 
                   A plasma homocysteine level more than 22µmol/liter increases the 
odds ratio of 4 for recurrent venous thromboembolism. 
 
  
 
HOMOCYSTEINE HAS BEEN LINKED TO VASO-OCCLUSIVE 
DISEASES IN THE EYE(58)  : 
 
Ocular complications associated with Homocysteine include  
• Ectopia lentis,  
• Secondary glaucoma,  
• Optic atrophy,  
• Age-related macular degeneration (ARMD),  
• Central retinal vein occlusion (CRVO), and  
• Diabetic retinopathy  
 
HOMOCYSTEINE AND OSTEOPOROSIS(59): 
                   Homocysteine elevation may weaken the bone by interfering with 
collagen cross linking, thereby increasing the risk of osteoporotic fracture. 
 
Methods used for Measuring Homocysteine Concentrations : 
Measurement of  Homocysteine levels by using
 
 
• High-Performance Liquid Chromatography (HPLC): it can be detected 
during HPLC as a fluorescent derivative or by direct electrochemical 
detection. Competitive immunoassays for homocysteine are available in the 
clinical laboratory enabled more laboratories to perform this test. These 
  
assays are based on quantitative enzymatic conversion of Homocysteine to 
S-adenosylhomocysteine.  
• CE-LIF- capillary electrophoresis with laser induced fluoresce detection, 
electrochemical detection, EIA-enzyme immune assay(60), LC-liquid 
chromatography, and UV-ultra violet. 
• Simple colorimetric enzyme assays for Homocysteine, to be performed on 
routine clinical chemistry analyzers. These are based on either an enzymatic 
cycling assay
 
or on enzymatic release of hydrogen sulfide which reacts to 
form a chromogen. 
• Another option is Tandem mass spectrometry. 
All methods appear to offer adequate analytical performance for routine clinical 
use. Choice of method therefore usually will depend on practical considerations of 
cost, labor efficiency, and which analyzers are already available in the laboratory. 
There is a trend for an increasing number of clinical laboratories to use routine 
chemistry analyzers rather than immunoassay or HPLC methods.  
  
TREATMENT OF HYPERHOMOCYSTEINEMIA 
                       Plasma homocysteine level is influenced by many factors like 
genetic determinants, lifestyle habits and physiological conditions. Among these 
factors dietary intake of vitamin B6, B12 and folate is a major determinant.  
  
                     Plasma homocysteine level is inversely related to dietary intake of 
these vitamins. Persons following strict vegetarian diet may develop vitamin B12 
deficiency. Studies have shown increased serum homocysteine level in vegetarians 
compared to non-vegetarians (61). 
                    Several studies have been conducted to assess the reduction in plasma 
homocysteine level with supplementation of vitamin B6, B12 and folate.  
                     A study conducted by Martin den Heijer, Ingeborg A. Brouwer and et 
al(62)showed that supplementation of 0.5µg of folic acid reduces homocysteine 
level by25% (range  -54% to 40%) and supplementation of 0.4mg of hydroxyl 
cobalamine reduces homocysteine level by 10% (range -21% to 41%). 
 
TREATMENT REGIMENS:- 
 Nutritional supplementation:  
 B12 vitamin is found in foods of animal origins. Food sources: Table-18: 
FOOD( B12) AMOUNT (mcg)/100 Gms of food 
Liver 70.58 
Seafood 6.88 
Eggs 1.11 
Beef Hamburger 2.50 
Salmon 2.80 
    
  
 
 Folic acid – found in  
o Green leafy vegetables such as spinach, broccoli, 
o Legumes such as lentils, chick peas, lima beans 
o orange. 
 Vitamin B6 - found in  
o Meat, poultry, fish, green leafy vegetables,  
o legumes, seeds, potatoes, cantaloupe, milk,  
o egg yolks, cereals, grains, wheat, wheat germ. 
 
 Betaine, a choline derivative, found in  
o Wheat Bran, Wheat Germ, Spinach, Beef Liver, Dried soybeans and 
Pork. 
 
                         Treatment of hyperhomocysteinemia is with supplementation of 
vitamin B6, B12 and folic acid. Effect of vitamin B12 and folic acid in the treatment 
of hyperhomocysteinemia is documented well in many studies. But the effect of 
vitamin B6 is not well established.  
 
 
  
o Regimen I: 
 650µg folic acid ,  
 100mg vitamin B6 along with 
 400µg vitamin B12  for  6 weeks.              
                    
o Regimen II: 
 5mg folic acid 
 250mg vitamin B6 for 12 weeks.                                 
 
CHOLESTEROL   LEVEL   IN  PREGNACY: 
                     Total plasma lipids  is 400-600 mg/dl. The lipids are insoluble in 
water, so it complex with proteins to form lipoproteins. The protein part of 
lipoprotein called apolipoprotein. 
Classification of lipoproteins:  
Depending upon the density, or electrophorotic mobility, the lipoprotein classified 
into 5 major types. 
1. Chylomicrons 
2. Very low density lipoprotein or pre-beta lipoprotein 
3. Intermediate density lipoprotein or broad- beta lipoprotein 
  
4. Low density lipoprotein or beta lipoprotein 
5. High density lipoprotein or alpha-lipoprotein. 
Total cholesterol = High density lipoprotein + Low density lipoprotein + 
(0.2×triglycerides). 
VALUES : Table-19: 
 
Total 
cholesterol(MG/DL) LDL(MG/DL) TG(MG/DL) 
Normal Less than 200 100 to 129 Less than 150 
Border 
line 200 to 239 130 to 159 150 to 199 
high         More than 240 More than 160 More than 200 
 
                      Marked elevations of total plasma cholesterol and triglyceride 
levels(63) is present during pregnancy due to increased liver synthesis of 
triglycerides(TG). TG in particular rise disproportionately in comparison to other 
lipid fractions reaching two to four times pre-pregnancy levels by the third 
trimester(64).  
                             And in response to elevated oestrogen levels Very Low Density 
Lipoprotein-Cholesterol (VLDL-C) also increased. Reduction in Lipoprotein lipase 
(LPL) activity due to the down regulation of LPL gene expression by oestrogen 
  
during pregnancy decreases the clearance of VLDL-C. Maternal factors(65) are 
highly influence on lipid profiles such as  
  Body mass index,   
 Weight gain of pregnant women,  
 Nutrition of the pregnant women,   
 Pre-pregnancy lipid levels and  
 Medical complications of pregnancy also have significantly affects the lipid 
metabolism and plasma lipid levels. 
                     During the first trimester, there is marked deposition and hypertrophy 
of maternal adipocytes with increased expression of insulin receptors such that 
glucose is available to meet the metabolic demand of the growing fetus.  
 Increase in maternal insulin and progesterone leads to  
o Lipogenesis with diminished lipolysis, and  
o Increased production of lipids, which are transported across the 
placenta and metabolized. This  signifies the essential role of lipids 
to normal fetal development. 
                     Cholesterol levels start to rise in the second trimester of gestation and 
peak during the third trimester. However, these changes are generally non-
atherogenic, and fall precipitously to pre-pregnancy levels around 4 weeks of post 
  
partum period. Cholesterol levels dropped most quickly in women who is 
breastfeeding their babies.  
 
LIPIDS AND HYPERTENSIVE COMPLICATIONS IN PREGNANCY: 
1. Chronic hypertension, where elevations in blood pressure precede the 
conception. 
2. Gestational hypertension, is elevated blood pressure without proteinuria 
occurring during pregnancy. 
3.  Preeclampsia is defined by new-onset gestational hypertension and 
proteinuria occurring in approximately 5-8% of pregnancies and is a major 
source of maternal and fetal morbidity and mortality(66,67) 
PATHOGENESIS:  
 Inadequate remodeling of the placental vasculature, leading to reduced 
placental perfusion.  
 Uterine vascular hypoplasia along with maternal factors of genetics, 
hypertension, diabetes, obesity, androgen secretion, and black race, then lead to 
the maternal manifestation of preeclampsia, with associated endothelial 
dysfunction and marked systemic inflammation. 
  
  Preeclampsia that is associated with more pronounced hypertension, oliguria, 
non-cardiogenic pulmonary edema, elevated liver enzymes, thrombocytopenia 
of less than 100,000/m3, and neurologic deficits is classified as severe disease. 
 
 
LIPIDS AND DIABETES MELLITUS IN PREGNANCY: 
 
                           Lipid profiles in women with preexisting uncomplicated DM of 
type 1 is similar to healthy women without diabetes(68). But risk factors such as 
obesity, hypertension, poor glycemic control, and preeclampsia, type 1 DM is 
associated with higher elevations in first trimester TG levels and lower levels of 
HDL-C in comparison to normal pregnancy. 
                         Women with preexisting type 2 DM have higher TG and lower 
HDL-C levels during the first trimester without significant change in LDL-C and 
Lp(a) levels in comparison to normal(69).            
                      Women with gestational diabetes may have increased to unchanged 
TG and TC levels and stable LDL fractions throughout gestation although these 
results have been equivocal. 
                     Maternal obesity, on the other hand, with or without overt gestational 
diabetes, is associated with atherogenic lipid profiles and poor pregnancy 
outcomes, due to inflammation and endothelial dysfunction(70).  Obese pregnant 
  
women is more frequently associated with elevated TG and small, dense LDL 
fractions with low HDL-C levels. Obese mothers will give large for gestational 
age, and may risk for  cardiovascular events later in life. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
AIM AND OBJECT 
1. To estimate serum homocysteine in gestational diabetes mellitus. 
2. To compare the serum homocysteine levels in gestational diabetes mellitus 
and in normal pregnancy. 
 
 
 
 
 
 
 
 
 
 
 
  
 
                            MATERIAL AND METHODS 
 SETTING                                        : Inpatients, 
                                                       Thanjavur medical college hospital,                                                                                          
       Obstetrics and Gynecology department, 
                                                            Thanjavur. 
 
ETHICAL COMMITTEE APPROVAL       :           Obtained. 
DESIGN OF STUDY                                    :       Single centre   prospective                                       
                                                                                Observational  study. 
PERIOD OF THE STUDY                            :       December 2013  
                                                                                 to June 2014 
SAMPLE SIZE                                              :       50 patients.  
 
 
 
 
 
 
 
  
 METHOD OF COLLECTION OF DATA: 
                           The present study was done on 50 patients admitted to RMH 
department of Obstetrics and Gynaecology department Thanjavur medical college, 
Thanjavur. Out of 50 patients, 20 patients were normal pregnancy and 30 patients 
were diagnosis as GDM with glucose challenge test and confirmed by OGTT as 
per WHO criteria and ADA criteria. A detailed history and thorough clinical 
examination was done as per proforma and investigated further. 
 
SELECTION OF THE PATIENT: 
INCLUSION CRITERIA:   
• Gestational diabetic mellitus in primi gravida  
• Gestational diabetic mellitus in multi gravida  and  
• Normal pregnancy. 
EXCLUSION CRITERIA: 
• Type 1 diabetes mellitus 
• Known case of type 2 diabetes mellitus 
• Family history of  diabetes mellitus 
• Coronary artery disease 
• Chronic kidney disease. 
 
  
 
 
STUDY METHODOLOGY: 
                           Totally 50 patients  were estimated for serum homocysteine level. 
In that 20 patients of normal pregnancy were under the  control groups. Out of that 
10 primi and 10 multi gravid. Another 30 patients were newly diagnosed 
gestational diabetes mellitus, out of that 15 patients were primi and another 15 
patients were multigravida.  
                          Only newly diagnosed GDM patients were included in this study 
and  excluding other risk factor such as Type 1 diabetes mellitus, Known case of 
diabetes mellitus, Family history of  diabetes mellitus, Coronary artery disease and 
Chronic kidney disease. Diagnosis of GDM was made by characteristic history, 
urine sample for sugar, random blood sugar. and confirmed with 1stGlucose 
challenge test , if  1 hour post glucose test value >14o mg /dl then,  we did oral 
glucose tolerance test. 
 
INVESTIGATIONS; 
The following investigations were done . 
• Fasting Serum homocysteine level, 
• Complete hemogram,  
• Fasting blood sugar, post prandial blood sugar, 
  
• Renal function test (urea, creatinine), 
• Lipid profile –Total cholesterol and Triglyceride, 
• Glucose  challenge   test, 
• Oral Glucose tolerance  test, 
• Urine sugar , 
•  VCTC, 
• Ultra sonogram for fetal well being and ECG. 
 
MEASUREMENT OF HOMOCYSTEINE LEVEL: 
                  Serum homocysteine level were estimated with using  Flurorescense 
Polarisation  Immuno Assay(FPIA) 
 
PRINCIPLE OF THE PROCEDURE: 
                  First step is oxidized form of homocysteine  is reduced to free form of 
homocysteine by use of dithiothreitol.  
                Second step is, in the presence of SAH hydrolase and excess adenosine, 
the reduced homocysteine converted into S-adenosyl- L –homocysteine(SAH).                                                    
                                                           SAH hydrolase 
Free form of homocysteine +adenosine  SAH  +  H2O. 
 
  
This mixture containing SAH, antibody, FPIA diluent buffer and a tracer tagged 
with a fluorescent chromophore were added to the cuvette. There will be 
competition between SAH from the serum sample and the fluorescent tagged tracer 
to bind with the antibody. Then the intensity of the polarized fluorescent light is 
measured using FPIA optical assembly. 
 
SPECIMEN COLLECTION AND STORAGE: 
                       From each patients Four ml of blood collected in EDTA coated tube. 
Samples were stored in 2-8 degree if testing was delayed. Centrifugation used for 
serum separation. 
 
STATISTICAL ANALYSIS: Data were analyzed  statistically described with  
1. Mean ± standard deviation (± SD),  
2. Range,  
3. Frequencies (number of cases) and relative frequencies (percentages) when  
appropriate.  
For comparing categorical data,  
1. Chi square (X 2) test was performed.  
2. A probability value (p value) less than 0.05 was considered statistically 
significant.  
  
 
OBSERVATION AND RESULTS 
                     50 patients were included in this study, serum homocysteine level 
estimated in all  patients. Among 50, 20 normal pregnant women were control 
group. 30 patients were newly diagnosis as gestational diabetes mellitus. 
TOTAL PARTICIPANTS: Table-20: 
PARTICIPANTS N=50 PERCENTAGE   (100%) 
Control 20 40.0 
Study 30 60.0 
FIGURE : 1 
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CONTROL GROUP 20 PATIENTS: Table-21: 
Total normal pregnant women 20 
Primi gravid 10 
Multi gravid 10 
 
GESTATIONAL DIABETES 30 PATIENTS: Table-22: 
Total normal pregnant women 30 
Primi gravid 15 
Multi gravid 15 
 
AGE GROUP: By using T-test, we calculated the mean, standard deviation  and  
‘p ‘value. Table-23: 
AGE MEAN S.D STATISTICAL INFERENCE 
Control(n=20) 24.25 4.102 T=-1.451 Df=48 
.153>0.05 
Not Significant 
Study(n=30) 25.83 3.553 
  
 
 Mean age group of control group is 24.25 years.  Among  them, 12 patients are the 
age between 18 to 25years.And 8 patients are between 26 to 33 years ofage. 
Table-24: 
AGE OF 18 TO 25 YEARS 12 (60 %) 
AGE OF 26 TO 33 YEARS 8 (40%) 
 
FIGURE : 2 
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IN  GDM  PATIENTS ; 
Mean age group of gestational diabetes patients is 25.8. Among them,13 patients 
are the age between 18 to 26 years, and 17 patients are between 27  to 32 years of 
age. Table-25: 
 AGE OF 18 TO 26 YEARS           13(11 primi,2 multi)(43.33%) 
AGE OF 27 TO 33 YEARS           17(4 primi,13 multi)(56.66%) 
 
FIGURE : 3 
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In the age group between 18 to 26 years, there are 11 primi and 2 multi gravida and 
between 27 to 33 years, there are 4 primi and 13 multi gravida.  FIGURE : 4 
 
 
GLUCOSE CHALLENGE TEST: 
                       Screening test of glucose challenge test done in all patients with 50 g 
of glucose and its values are statistically interpreted. ‘P’ values are significant 
(<0.005). Table-26: 
GCT MG.DL MEAN S.D 
STATISTICAL 
INFERENCE 
Control(n=20) 114.5000 20.87683 T=-8.797 Df=48 
.000<0.05 
Significant 
Study(n=30) 162.4667 17.46274 
0
2
4
6
8
10
12
14
AGE 18-26 AGE 27-33
PRIMI 11 4
MULTI 2 13
11
4
2
13
  
 
In normal pregnancy , three women’s had  > 140 mg of blood sugar value,  others 
had normal values of <140 mg/dl. The mean GCT values  is 114.50. The standard 
deviation is 20.87. 
Table-27: 
<  140 mg /dl of  blood sugar at 1 hour 17 (85%) 
> 140 mg /dl of  blood sugar at 1 hour 3 (15%) 
 
FIGURE : 5 
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In GDM: patients the mean values of GCT is 162.42. the standard deviation is 
17.46. 
 
GCT  values :   17 patients had    >140 to 160 mg/dl.    13 patients had > 
160mg/dl. 
 
    Table-28:  
 >140 to 160 mg/dl     17 (56,6 %) 
 160 mg/dl     13 (43.3%) 
FIGURE : 6 
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FIGURE : 7 
 
 
 
                   
               After glucose challenge test ,we did oral glucose tolerance test after 
overnight fast with 100 gm of glucose to conform the glucose intolerance, Almost 
all the gestational diabetes group patients had abnormal OGTT test reports .Among 
30 patients , 2 patients is under diet control and 28 patients are started on insulin 
therapy . 
                 And we did fasting and postprandial blood sugar in all patients of both 
groups. And results were interpreted along with OGTT.          
0
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FASTING BLOOD SUGAR:  
      We collect the blood sample at 8 am for fasting blood sugar.  Normal value is < 
95 mg/dl. In control group mean values of fasting blood glucose level 85.60 and 
standard deviation is 8.531. In case of GDM, mean of 116.4 and SD is 10.85 with 
significant ‘p’ values. 
 
Table-29: 
 
           FBS   MEAN   SD    STATISTICAL INFERENCE 
 Control(n=20)    85.60   8.531 
      T=-10.667 Df=48 
      .000<0.05 
      Significant 
  Study(n=30)   116.40  10.858 
 
  
  
 
 
POST PRANDIAL BLOOD SUGAR : 
 
              We collected the blood sample from all patients after 2 hours of  glucose. 
The report showed  that normal pregnant women had less than 140 mg/dl . 
    In control group mean values of post prandial blood glucose level 127.95 
and standard deviation is 9.944. In case of GDM, mean of 193.23 and SD is 12.32 
with significant ‘p’ values. 
Table-30: 
 
      PPBS     MEAN      SD STATISTICAL INFERENCE 
 Control(n=20)    127.95     9.944 
      T=-19.768 Df=48 
      .000<0.05 
       Significant 
 Study(n=30)    193.23    12.322 
 
  
  
 
 
 
HOMOCYSTEINE LEVEL : 
 
 
                  In normal pregnant women had the values of < 5 micro mol/l.  Among 
the GDM patients 17  patients had  elevated homocysteine level  and 13 patients 
had normal .But when compare to normal pregnant women 29 patients elevated 
level that is > 8.micromol/l.  
 
Table-31: 
 
 Homocysteine  MEAN     SD 
 STATISTICAL                           
INFERENCE 
Control(n=20)  3.8600   .95038 T=-9.024 Df=48 
.000 < 0.05 
Significant Study(n=30)  16.3040   6.09711 
 
 
 
  
 
The mean value of homocysteine in control group is 3.8 ± 0.95 and in gestational 
diabetes patients is 16.30 ± 6.09. Its ‘p’ value is significant. 
Homocysteine level in gestational diabetes mellitus group: Table-32: 
<  15 µmol/l 13 (43.33%) 
 15 µmol/l 17 (56.66%) 
 
FIGURE : 8 
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HYPERHOMOCYSTEINEMIA COMPARING PRIMI AND MULTI PARA: 
                   Out of 13 patients with normal homocysteine, 7 patients are  primi and 
6 patients are multi gravid. And among the 17 patients with elevated 
homocysteine, 8 patients  are primi and 9 patients are multigravida. 
 
 
56.66%
43.33%%
HYPERHOMOCYSTEINEMIA NORMAL HOMOCYSTEINE
HOMOCYSTEINE IN GDM
  
 
Normal homocysteine in GDM :  primi vs multi: 
 7 PRIMI(53.8%) 
 13 PATIENTS   
 6 MULTI(46.1%) 
 
Normal homocysteine level in gestational diabetes mellitus: This pie diagram 
showed primi vs multi with normal HCY level. 
FIGURE : 10 
 
 
 
HYPERHOMOCYSTEINEMIA IN GDM : PRIMI VS MULTI: 
 
  8 PRIMI ( 47%) 
17 PATIENTS    
 
       9 MULTI (53%). 
7 patients
(53.9%)
6 patients
(46.1%)
PRIMI  VS  MULTI
primi
multi
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TOTAL CHOLESTEROL LEVEL IN PREGNANCY: 
                     Total cholesterol level is significantly elevated in gestational diabetes 
patients.The mean value of Total cholesterol in control group is 187.70±18.2and in 
gestational diabetes patients is 211.50 ± 28.799. Its ‘p’ value is significant  
( p=0.002). 
 
 
 
 
 
8 PATINTS 
(47%) 
PATIENTS 
(53%)
IN GDM PRIMI  VS  MULTI
primi
multi
  
Table-33: 
 
TC MEAN SD 
STATISTICAL 
INFERENCE 
Control(n=20) 187.70 18.270 
T=-3.276 Df=48 
.002<0.05 
Significant 
Study(n=30) 211.50 28.799 
 
Total cholesterol level is elevated in 18 patients of gestational diabetes patients,  
Table-34: 
 
TOTAL CHOLESTEROL < 200 MGS/DL > 200 MGS/DL 
Control group(20 patients) 15 ( 75 %) 5 (25 %) 
Study group(30 patients) 12 (40%) 18 (60%) 
 
 
  
 
 
In control group: among the 20 patients, 5 patients had mild elevation of Total 
cholesterol level( 25%)  and 15 patients had the normal level of Total 
cholesterol(75%).  
FIGURE : 12 
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TRIGLYCERIDE LEVEL IN PREGNANCY: 
In our study, 12 patients of gestational diabetes patients had elevated TG level. In 
control group, all had the normal triglyceride level. 
 
The mean value of triglyceride level is 113.30 ± 16.10 in control group. In study 
group (gestational diabetes patients) the mean value is 140.20 ± 22.15. ‘p’ value is 
< o.oo5. 
 
TG MEAN SD 
STATISTICAL 
INFERENCE 
Control(n=20) 113.30 16.102 T=-4.664 Df=48 
.000 < 0.05 
Significant 
Study(n=30) 140.20 22.154 
 
 
 
 
 
 
 
 
  
 
Table-35: 
 
TRIGLYCERIDE 
LEVEL 
< 150 mg/dl >150 mg/dl 
Control group(20 
patients) 
20 Nil 
Study group(30 patients) 18 (60%) 12 (40%) 
 
FIGURE : 15 
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DISCUSSION 
 
                         Homocysteine  is naturally  obtained by diet containing  methionine  
which is one of the essential amino acid. The role of homocysteine as an 
independent risk factor of gestational diabetes mellitus has not been extensively 
studied in India. Due to multiple factor like dietary, life style, socio economic 
status and other ethnic differences, the results found in the western studies cannot 
be applicable to our population. 
                         The mean homocysteine level in control group is (3.8 ±0.95 
µmol/L) is similar to that reported by Walker and associates in a Canadian 
population between 20 and 28 weeks' gestation (2.7±1.3µmol/L) in normal glucose 
tolerance test. 
                          The mean serum homocysteine concentration in women with 
gestational diabetes mellitus in our study was significantly higher than that in 
normal pregnant controls between 24-28 weeks gestation (16.30 ± 6.09 µmol/L and 
2.7 ± 1.3 µmol/L respectively. These results are comparable to the levels detected 
in GDM patients in previous analysis.  
                         Also, Guven group(71)  found higher homocysteine levels GDM 
patients compared to normal pregnant women, but they reported lower estimates 
(9.0 ± 3.1µmol/L and 7.4 ± 1.6µmol/L respectively).  
  
                    Another the Cotton's study(72) explained the higher levels, which 
demonstrated that  homocysteine level may show a various range in a various 
population and may elevate up to sixteen µmol/L  for  97.5 percentile in normal 
healthy individual.  
                          However, Vitoratos et al(73)was not find a statically significant 
different homocysteine levels between GDM patients (n=15), and glucose tolerant 
pregnant controls (n=21), it may due to their studied population which was small 
and was late in the third trimester. 
                  In our present study, significant positive correlation was found between, 
total cholesterol, triglyceride and homocysteine levels in GDM patients. It has been 
well documented  by older studies that in diabetes, serum homocysteine levels are 
directly related to insulin resistance, especially when associated with the presence 
of vascular complications.  
                 In Some studies there was reduction in serum homocysteine level in 
gestational diabetes after supplementation with vitamin B12 , folate and B6. But it 
requires large scale study and long term follow up to evaluate the outcome. 
                   Gestational diabetes mellitus is associated with abnormal endothelial 
function. Schaich et al(74)reported that even slightly elevated homocysteine levels 
also to be of crucial importance for the endothelial dysfunction, especially when 
associated with other risk factors such as hypercholesterolemia co-exist. 
  
Additionally, it has been reported that even in normal ranges cholesterol levels 
may be associated with impaired homocysteine metabolism and endothelial 
dysfunction. 
                 There was  significant elevation of total cholesterol concentrations in 
gestational diabetes mellitus compared with control group of normal pregnant. In 
our study, GDM significantly alters serum cholesterol metabolism leading to 
dyslipidemia. These findings  co-relate with reports by Amraei and Azemati  done 
in pakistan who reported significant difference in total cholesterol levels between 
pregnancy complicated by GDM and normal pregnancy. 
.                These changes of increased levels of serum triglycerides, total 
cholesterol and LDL cholesterols observed in GDM is due to the result of 
increased fat storage and progesterone level in the second trimester of pregnancy. 
This action may be  due to the reset of the lipostat in the hypothalamus leading to 
increase in the lipids concentration . 
  
  
 
STRENGTHS OF THE STUDY 
 
 In our study patients without conventional risk factors presented with gestational 
diabetes mellitus were selected and the role of serum homocysteine was studied in 
these patients. So, the role of serum homocysteine has been assessed as an 
independent risk factor for gestational diabetes mellitus. 
 We included patients of both primi and multi gravida with age group of 18 to 33 
years and compared the role of serum homocysteine level in patients with primi 
and multi gravida. Homocysteine is found to be a significantly elevated in multi 
gravida (53 %) compare to primi (47%) in gestational diabetes mellitus. 
  We also compared the homocysteine levels between normal pregnancy and in 
gestational diabetes mellitus.  Hyperhomocysteinemia is significantly elevated 
among gestational diabetes mellitus (56.66%). 
 We compared the total cholesterol level between normal pregnancy and in  
gestational diabetes mellitus. Total cholesterol level is significantly elevated 
among gestational diabetes mellitus ( 60 %). 
 And also triglyceride level between normal pregnancy and in  gestational diabetes 
mellitus, triglyceride level elevated in 40 % of the gestational diabetes mellitus. 
 
  
                         
                                    LIMITATIONS OF THE STUDY 
 Sample  size is very small , and  
 Our study lack the knowledge of homocysteine status of the patient before the 
diagnosis of the gestational diabetes mellitus. 
 In this study we did not evaluate the role of other risk factors of gestational 
diabetes mellitus like insulin level, sensitivity of insulin, vitamin B12 , B6 and 
folate level. whether these factors also plays a role in development of  
gestational diabetes mellitus in the absence of conventional risk factors is not 
studied. This is the limitation of the study. 
 
 We did not evaluate the association between severity and outcome of maternal 
status and also fetal outcome with serum homocysteine levels. Also we did not 
evaluate whether the reduction of serum homocysteine by treatment will 
prevent the future type 2 DM, or recurrence of gestational diabetes mellitus in 
subsequent pregnancy. Further studies involving large sample will be needed to 
confirm this.  
  
CONCLUSION 
 
 The mean age groups of controls and cases were 24.25 ± 4.102 and 25.83 ± 
3.553 years.   
 The mean serum homocysteine level was significantly higher in diabetic 
patients compared to controls (P=0.000). 
 Hyperhomocysteinemia is found in 56.66% of patients with gestational 
diabetes mellitus. 
  Hyperhomocysteinemia is found to be an independent risk factor for 
gestational diabetes mellitus patients. 
 Among the control group of normal pregnant women and the study group of 
gestational diabetes mellitus, serum homocysteine level  is found to be 
significantly elevated in gestational diabetes mellitus. 
 Among the study groups, the incidence of hyperhomocysteinemia is  53% in 
multi gravida and 47% in primi gravida.  
 Whether serum homocysteine is directly associated with GDM or it may 
cause deterioration of glucose tolerance, remains  Unclear. 
 Only well-designed large trials with vitamin B12, vitamin B6 and  folic acid 
supplementation will be able to give more clear explanations. 
  
 Vitamin B12, vitamin B6  and Folic acid supplementation with higher dose 
throughout pregnancy will change the plasma homocysteine concentration. 
This simple, safe and inexpensive intervention may therefore play a 
preventive role. 
 The average levels of Total cholesterol, were significantly found to be 
higher in GDM cases compared to controls. 
 The average levels of Triglyceride were elevated in 40% of GDM cases. 
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                                   CONSENT FORM 
 
I __________________________________________  hereby give consent to 
participate in the study conducted by DR.R.SHARMILA, post graduate in 
department of internal medicine ,Thanjavur medical college & Hospital, Thanjavur 
– 613001 and to use my personal clinical data and result of investigation for the 
purpose of analysis and to study the nature of disease. I also give consent for 
further investigations. 
 
 
Place : 
Date :       Signature of participant 
 
 
 
 
 
 
 
 
 
 
 
 
  
A COMPARATIVE AND CORRELATIVE STUDY OF SERUM 
HOMOCYSTEINE LEVEL IN GESTATIONAL DIABETES MELLITUS 
AND NORMAL PREGNANCY 
 
                                                 PROFORMA 
PATIENT NAME;                                                             DOA: 
AGE:                                                                                 DOD: 
SEX:                                                                          OP/IP NO: 
OCCUPATION: 
ADDRESS: 
 CHIEF COMPLAINT: 
 
 HISTORY OF PRESENTING ILLNESS: 
 Frequent urination: 
 Excessive thirst: 
 Unexplained weight loss: 
 Extreme hunger: 
 Sudden vision changes: 
 Tingling or numbness in the hands or feet: 
 Feeling very tired much of the time: 
 Very dry skin: 
  
 Gravida : Primi / G1 / G2 / G3 
 Para: P1 / P2 / P3 
 living child: 
 History of Abortion: 
 Past History :Hypertension / DM / CAHD 
 Family History: 
 Personal History: 
 Diet: 
                     EXAMINATION OF THE PATIENT: 
 
 GENERAL EXAMINATION: 
o Build And Nourishment: 
o Pallor; 
o Icterus: 
o Clubbing: 
o Cyanosis: 
o Pedal edema: 
 VITAL SIGNS:     
Pulse:                       Blood pressure: 
                           Respiratory rate:                     Temp: 
  
 Cardiovascular System Examination:  
                             
 Respiratory System Examination: 
 
 Per Abdominal Examination: 
 
 Central Nervous System Examination: 
 
                                 INVESTIGATION 
Urine;   Albumin: 
                    Sugar: 
               Deposits: 
Complete Hemogram: 
                   HB:                       RBC:               PCV: 
                  TC:                        PLT: 
                  DC:                       ESR: 
 
Random Blood Sugar: 
 
 
  
Renal Function Test: 
             Urea: 
     Creatinine: 
Serum Electrolytes: 
         Pottasium: 
           Sodium: 
Serum Homocysteine Level: 
VCTC:   Reactive / Non Reactive 
Oral Glucose Tolerance Test: 
          Fasting: 
          1 Hour: 
          2 Hour: 
          3 Hour: 
Electrocardiogram: 
 
Ultra sonogram for fetus: 
 
 
 
  
 
  
  
  
 
  
  
 
